var title_f13_38_13920="ARDS PA";
var content_f13_38_13920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Acute respiratory distress syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray showing diffuse, bilateral, alveolar infiltrates without cardiomegaly in a patient with ARDS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13920=[""].join("\n");
var outline_f13_38_13920=null;
var title_f13_38_13921="Midface motion examination";
var content_f13_38_13921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Examination for abnormal midface motion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To assess for abnormal midface&nbsp;instability, grasp the superior anterior teeth (or alveolar ridge if teeth are absent) between the thumb and index finger and attempt to move the maxilla anteriorly and posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harwood-Nuss, A, Wolfson, AB, et al. The Clinical Practice of Emergency Medicine, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13921=[""].join("\n");
var outline_f13_38_13921=null;
var title_f13_38_13922="Colonic stent Endosc";
var content_f13_38_13922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Self expanding metal stent in a patient with colon cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic images of an obstructing sigmoid colon cancer (left panel). A blue guidewire (visible at the base of the stricture) has been passed through the stricture under fluoroscopy. The right panel shows the fully-deployed stent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Todd H. Baron, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13922=[""].join("\n");
var outline_f13_38_13922=null;
var title_f13_38_13923="Quebec back pain scale";
var content_f13_38_13923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Quebec back pain disability scale*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 780px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Minimum detectable change (90% confidence): 15 points.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kopec JA, Esdaile JM, Abrahamowicz M, et al. The Quebec Back Pain Disability Scale: Measurement properties. Spine 1995; 20:341. Copyright &copy; 1995 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13923=[""].join("\n");
var outline_f13_38_13923=null;
var title_f13_38_13924="Diazoxide: Drug information";
var content_f13_38_13924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diazoxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/47/43763?source=see_link\">",
"    see \"Diazoxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/11/13492?source=see_link\">",
"    see \"Diazoxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Proglycem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Proglycem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote, Hypoglycemia;",
"     </li>",
"     <li>",
"      Vasodilator, Direct-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hyperinsulinemic hypoglycemia:",
"     </b>",
"     Oral: Initial dose: 3 mg/kg/day; dosing range: 3-8 mg/kg/day in divided doses every 8-12 hours.",
"     <b>",
"      Note:",
"     </b>",
"     In certain instances, patients with refractory hypoglycemia may require higher doses.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F159147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/11/13492?source=see_link\">",
"      see \"Diazoxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperinsulinemic hypoglycemia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Newborns and Infants: Initial dose: 10 mg/kg/day; dosing range: 8-15 mg/kg/day in divided doses every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F159137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life may be prolonged with renal impairment; a reduced dose should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proglycem&reg;: 50 mg/mL (30 mL) [contains ethanol ~7.25%, propylene glycol, sodium benzoate; chocolate-mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10241396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Proglycem&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypoglycemia related to islet cell adenoma, carcinoma, hyperplasia, or adenomatosis; nesidioblastosis; leucine sensitivity; extrapancreatic malignancy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F159165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diazoxide may be confused with diazepam, Dyazide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, headache, insomnia, malaise, polyneuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hirsutism, pruritus, purpura, rash, scalp hair loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast lump enlargement, diabetic ketoacidosis, fluid retention, galactorrhea, gout, hyperglycemia, hyperosmolar nonketotic coma, sodium retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, ileus, nausea, pancreatitis, pancreatic necrosis, taste loss (transient), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding (excessive), eosinophilia, hemoglobin/hematocrit decreased, neutropenia (transient), thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cataracts (transient), diplopia, lacrimation, ring scotoma, subconjunctival hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, azotemia, creatinine clearance decreased, glucosuria, hematuria, nephrotic syndrome (reversible), uric acid increased, urinary output decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Abnormal facial features (children with chronic use), IgG decreased, lymphadenopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diazoxide, thiazides, or other sulfonamide derivatives; functional hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use may lead to increased fluid retention and may precipitate congestive heart failure in patients with compromised cardiac reserve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: Use with caution in patients with hyperuricemia or a history of gout.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; a reduced dose should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperosmolar coma: Nonketotic hyperosmolar coma may occur during treatment; usually in patients with concomitant illness. Transient cataracts have been reported which subside following correction of hyperosmolarity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ketoacidosis: Ketoacidosis may occur during treatment, usually in patients with concomitant illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Newborns: May displace bilirubin from albumin; use caution in newborns with hyperbilirubinemia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: Diazoxide may enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Diazoxide may decrease the serum concentration of Fosphenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Diazoxide may decrease the serum concentration of Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5636013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid herbs with hypotensive properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of diazoxide. Avoid herbs with hypertensive properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of diazoxide.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5636010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal studies. Diazoxide crosses the human placenta. Altered carbohydrate metabolism, hyperbilirubinemia, or thrombocytopenia have been reported in the fetus or neonate. Alopecia and hypertrichosis lanuginosa have also been reported in infants following maternal use of diazoxide during the last 19-60 days of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Proglycem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (30 mL): $255.01",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F159109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood glucose, serum uric acid, BUN, creatinine clearance, CBC with differential, AST; urine glucose and ketones",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Eudemine (GB);",
"     </li>",
"     <li>",
"      Hyperstat (BE, CZ, ES, HR, HU, LU, SE);",
"     </li>",
"     <li>",
"      Hypertonalum (DE);",
"     </li>",
"     <li>",
"      Naxproglycem (KP);",
"     </li>",
"     <li>",
"      Proglicem (AR, CH, DE, FR, IT, NL, NO, SG);",
"     </li>",
"     <li>",
"      Proglycem (GR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Activates potassium channels. Inhibits insulin release from the pancreas",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hyperglycemic: Oral: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Hyperglycemic: Oral: Normal renal function: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: Children: 9-24 hours; Adults: 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lancaster-Smith M, Leigh NI, and Thompson HM, &ldquo;Death Following Nonketotic Hyperglycemic Coma During Diazoxide Therapy and Peritoneal Dialysis,&rdquo;",
"      <i>",
"       Postgrad Med J",
"      </i>",
"      , 1974, 50:175-9.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9346 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13924=[""].join("\n");
var outline_f13_38_13924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159130\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159131\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159160\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159135\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159147\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159136\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159137\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796051\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159111\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10241396\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159095\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159112\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159165\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159158\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159117\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159099\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299180\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159104\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5636013\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159106\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5636010\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159138\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159119\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159109\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038599\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159098\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159116\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/47/43763?source=related_link\">",
"      Diazoxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/11/13492?source=related_link\">",
"      Diazoxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_38_13925="MRI findings Wernicke A";
var content_f13_38_13925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F82317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F82317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI findings Wernicke's encephalopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 20-year-old pregnant female with severe emesis and presumed Wernicke's encephalopathy. Flair images demonstrate typical findings of hyperintensity in the periaqueductal region of the midbrain (A), mammillary bodies (B), and thalamus (C). Additionally, the patient had bilateral symmetrical hyperintensity in the frontal-parietal cortices (D), which has also been reported in these patients.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13925=[""].join("\n");
var outline_f13_38_13925=null;
var title_f13_38_13926="Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children";
var content_f13_38_13926=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13926/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13926/contributors\">",
"     Elaine I Tuomanen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13926/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13926/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13926/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13926/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/38/13926/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    (",
"    <em>",
"     pneumococcus",
"    </em>",
"    ) is a leading cause of serious illness among children worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/1\">",
"     1",
"    </a>",
"    ]. Before universal infant immunization with pneumococcal conjugate vaccine (PCV) in the United States,",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    caused approximately 17,000 cases of invasive disease each year among children younger than five years of age, including 700 cases of meningitis and 200 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/2\">",
"     2",
"    </a>",
"    ]. It was the most frequent cause of bacteremia, pneumonia, meningitis, sinusitis, and acute otitis media.",
"   </p>",
"   <p>",
"    The development of the pneumococcal vaccine, the first vaccine derived from a capsular polysaccharide, is an important landmark in medical history. The polysaccharide antigens were used to induce type-specific antibodies that enhanced opsonization, phagocytosis, and killing of pneumococci by phagocytic cells. The tetravalent vaccine was first used in 1945. However, it was not widely distributed because its deployment coincided with the discovery of penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/3\">",
"     3",
"    </a>",
"    ]. Vaccination programs were largely abandoned because pneumococcal disease was so easily controlled by antibiotics. The development and increasing prevalence of multiple-antibiotic-resistant strains has once again made prevention of pneumococcal disease a priority. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of pneumococcal polysaccharide vaccines in children will be reviewed here. The use of conjugate pneumococcal vaccines in children and pneumococcal vaccination of adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surface capsular polysaccharide of",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    provokes a type-specific protective immune response and serves as the basis for serotyping of these organisms. More than 90 different pneumococcal serotypes have been identified. Serotypes 6, 14, 18, 19, and 23 are the most prevalent, accounting for between 60 and 80 percent of infections depending upon the area of the world. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23143?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology and pathogenesis of Streptococcus pneumoniae\", section on 'Capsule'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not possible to include all of the serotypes in a polysaccharide vaccine. Vaccines representing subgroups of the most prevalent serotypes causing invasive disease have been formulated. A 14-valent polysaccharide vaccine (PPSV14) was developed in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/4\">",
"     4",
"    </a>",
"    ]. The current 23-valent polysaccharide vaccine (PPSV23) was developed in 1983. Polysaccharide vaccines generally are not considered to be immunogenic in children younger than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], the age group with the highest incidence of invasive disease. The development of protein-polysaccharide conjugate vaccines was necessary to improve prevention of pneumococcal disease in these young children. Pneumococcal conjugate vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VACCINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available pneumococcal polysaccharide vaccines (Pneumovax&reg; 23, Pnu-Imune 23) include 23 purified capsular polysaccharide antigens (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) (",
"    <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"     table 1",
"    </a>",
"    ). Twenty-five micrograms of each capsular polysaccharide antigen is dissolved in isotonic saline solution with phenol (0.25 percent) or thimerosal (0.01 percent) added as preservative; there is no adjuvant. The 23 serotypes were chosen to represent 85 to 90 percent of the serotypes that cause invasive disease in the United States. A comparison of PPSV23 and the 13-valent conjugate pneumococcal vaccine (PCV13) is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef71746 \" href=\"UTD.htm?0/43/701\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DOSE AND ROUTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 23-valent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    is administered intramuscularly or subcutaneously as one 0.5 mL dose. It may be administered concurrently with other vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 23-valent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) is recommended for children &ge;24 months of age who are at high risk for invasive pneumococcal infection (",
"    <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/1,7,8\">",
"     1,7,8",
"    </a>",
"    ], including those who have, or are scheduled to receive, a cochlear implant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=see_link&amp;anchor=H17#H17\">",
"     \"Cochlear implant infections\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine use of PPSV23 after pneumococcal conjugate vaccine is no longer recommended for Alaska Native or American Indian children aged 24 through 59 months. However, in special circumstances, it may be recommended for such children living in areas where the risk of invasive pneumococcal disease is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommends a single dose of PPSV23 for persons aged 19 through 64 years who smoke cigarettes and for persons aged 19 through 64 years who have asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/10\">",
"     10",
"    </a>",
"    ]. This recommendation has not yet been extended to include children and adolescents younger than 19 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SCHEDULE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For children at high risk of invasive pneumococcal disease (",
"    <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"     table 3",
"    </a>",
"    ), the 23-valent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) should be administered at age &ge;2 years and &ge;8 weeks after the last indicated dose of pneumococcal conjugate vaccine (",
"    <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. A second dose of PPSV23, five years after the first, should be administered to children who are immunocompromised, have sickle cell disease, or have functional or anatomic asplenia. A second dose of PPSV23 is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for high-risk children who are immunocompetent (ie, those with cochlear implants or chronic disease, including chronic heart disease, chronic lung disease, diabetes mellitus, or cerebrospinal fluid leaks) (",
"    <a class=\"graphic graphic_table graphicRef79553 \" href=\"UTD.htm?23/60/24523\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 13-valent conjugate pneumococcal vaccine (PCV13) series should be completed at least two weeks before elective splenectomy, immune-compromising therapy, or cochlear implantation, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/1,9,12\">",
"     1,9,12",
"    </a>",
"    ]. PPSV23 can be given &ge;8 weeks after the last dose of PCV13. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Pneumococcal vaccine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=see_link&amp;anchor=H17#H17\">",
"     \"Cochlear implant infections\", section on 'Vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polysaccharide vaccines, including PPSV23, do not induce a T cell-dependent response, and, therefore, revaccination does not engender an anamnestic response. Long-term follow-up data concerning antibody levels in persons who have been revaccinated are not yet available. Routine revaccination of persons who have received two doses of PPSV23 as described above is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of persons who receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    develop mild, local side effects (eg, pain at the injection site, erythema, and swelling) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. These reactions usually persist for less than 48 hours. Moderate systemic reactions (eg, fever and myalgias) and more severe local reactions (eg, local induration) are rare. Revaccination after intervals of four years or more is not associated with an increased incidence of adverse side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMMUNOGENICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful vaccination is indicated by an antigen-specific antibody response of at least twofold in serotype-specific antibody within two to three weeks. However, the responses may not be consistent among all 23 serotypes in the vaccine. The concentrations of antibodies to most pneumococcal vaccine antigens remain elevated for at least five years in healthy adults. In some individuals, antibody concentrations decrease to prevaccination levels by 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polysaccharide vaccines generally are not considered to be immunogenic in children younger than two years. However, infants 6 to 12 months of age may respond to at least some of the antigens in the 23-valent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. The duration of the immune response and the effect of early administration on subsequent challenge require additional evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     In high-risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data regarding the immunogenicity of pneumococcal polysaccharide vaccines in children belonging to high-risk groups.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immunogenicity of the",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV) in children with chronic renal disease was evaluated in a prospective study in 41 children (mean age 12.4 years, range 2 to 21 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/20\">",
"       20",
"      </a>",
"      ]. Antibody titer to serotypes 3 and 14 were measured before, one month after, and one year after vaccination. At one month, 76 and 61 percent of patients had at least a twofold rise in antibody titer to serotype 3 and 14, respectively. At one year, the majority of patients continued to have protective antibody concentrations.",
"     </li>",
"     <li>",
"      Patients with sickle cell anemia and asplenia who received an 8-valent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      responded with at least a 1.5-fold antibody increase for all serotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children with human immunodeficiency virus (HIV) and low to moderate viral load receiving highly active retroviral therapy, the antibody response to two doses of the 7-valent conjugate pneumococcal vaccine (PCV7) followed by one dose of PPSV23 is comparable to that in healthy infants [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EFFICACY AND EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV) in children at increased risk for invasive pneumococcal disease (IPD) is not well studied. In adults, PPSV protects against invasive disease, including bacteremia and meningitis, but does not appear to prevent nonbacteremic pneumonia.",
"   </p>",
"   <p>",
"    The overall effectiveness of the PPSV in preventing meningitis and bacteremia caused by vaccine serotypes in individuals older than five years of age was estimated to be 57 percent (95% CI 45-66) using data from the Centers for Disease Control and Prevention&rsquo;s (CDC) pneumococcal surveillance system [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/23\">",
"     23",
"    </a>",
"    ]. In a similar analysis, the effectiveness of the 23-valent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) in preventing invasive disease caused by vaccine serotypes in 48 preschool children (two to five years) with chronic disease was estimated to be 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/24\">",
"     24",
"    </a>",
"    ]. The effectiveness against the 16 serotypes included in the PPSV23 but not in the 7-valent conjugate pneumococcal vaccine (PCV7) was 94 percent.",
"   </p>",
"   <p>",
"    An octavalent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    was shown to be effective in preventing IPD in children (aged 2 to 25 years) with sickle cell anemia or after splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13926/abstract/21\">",
"     21",
"    </a>",
"    ]. However, in this study the mean age of the 77 patients with sickle cell disease who were immunized was 11.3 years, and more than 80 percent were older than six years. Subsequent studies could not confirm the efficacy demonstrated in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pneumococcal protein conjugate vaccine is recommended for all children during infancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H13#H13\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Indications'",
"      </a>",
"      .) In addition, children &ge;2 years of age who are at risk for invasive pneumococcal disease (",
"      <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"       table 3",
"      </a>",
"      ) should receive the 23-valent",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/12/4294?source=see_link\">",
"       pneumococcal polysaccharide vaccine",
"      </a>",
"      (PPSV23). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PPSV23 should be administered at age &ge;2 years and &ge;8 weeks after the last indicated dose of pneumococcal conjugate vaccine (",
"      <a class=\"graphic graphic_table graphicRef62519 \" href=\"UTD.htm?20/63/21501\">",
"       table 4",
"      </a>",
"      ). A second dose of PPSV23, five years after the first, should be administered to children who are immunocompromised, have sickle cell disease, or have functional or anatomic asplenia. A second dose of PPSV23 is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for high-risk children who are immunocompetent (ie, those with cochlear implants or chronic disease, including chronic heart disease, chronic lung disease, diabetes mellitus, or cerebrospinal fluid leaks) (",
"      <a class=\"graphic graphic_table graphicRef79553 \" href=\"UTD.htm?23/60/24523\">",
"       table 5",
"      </a>",
"      ). Routine revaccination of persons who have received two doses of PPSV23 as described above is not recommended. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dose of PPSV23 is 0.5 mL administered intramuscularly. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dose and route'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately one-third of vaccinees develop mild local side effects that persist for less than 48 hours. More severe local reactions and moderate systemic reactions are rare. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/1\">",
"      Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/2\">",
"      Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/3\">",
"      Macleod CM, Hodges RG, Heidelberger M, Bernhard WG. PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES. J Exp Med 1945; 82:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/4\">",
"      Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/5\">",
"      Ghaffar F, Barton T, Lozano J, et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004; 39:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/6\">",
"      Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Pneumococcal vaccination for cochlear implant recipients. MMWR Morb Mortal Wkly Rep 2002; 51:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/8\">",
"      American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 2000; 106:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003; 52:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/11\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics 2010; 126:186.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Pneumococcal infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th Ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.571.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/13\">",
"      Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/14\">",
"      Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis 1984; 149:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/15\">",
"      Mufson MA, Krause HE, Schiffman G, Hughey DF. Pneumococcal antibody levels one decade after immunization of healthy adults. Am J Med Sci 1987; 293:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/16\">",
"      Pomat WS, Lehmann D, Sanders RC, et al. Immunoglobulin G antibody responses to polyvalent pneumococcal vaccine in children in the highlands of Papua New Guinea. Infect Immun 1994; 62:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/17\">",
"      Peset Llopis MJ, Harms G, Hardonk MJ, Timens W. Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. J Allergy Clin Immunol 1996; 97:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/18\">",
"      Sorensen RU, Leiva LE, Javier FC 3rd, et al. Influence of age on the response to Streptococcus pneumoniae vaccine in patients with recurrent infections and normal immunoglobulin concentrations. J Allergy Clin Immunol 1998; 102:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/19\">",
"      Balloch A, Licciardi PV, Russell FM, et al. Infants aged 12 months can mount adequate serotype-specific IgG responses to pneumococcal polysaccharide vaccine. J Allergy Clin Immunol 2010; 126:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/20\">",
"      Furth SL, Neu AM, Case B, et al. Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr 1996; 128:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/21\">",
"      Ammann AJ, Addiego J, Wara DW, et al. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med 1977; 297:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/22\">",
"      Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/23\">",
"      Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13926/abstract/24\">",
"      Fiore AE, Levine OS, Elliott JA, et al. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis 1999; 5:828.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6015 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13926=[""].join("\n");
var outline_f13_38_13926=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VACCINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DOSE AND ROUTE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SCHEDULE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMMUNOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      In high-risk groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EFFICACY AND EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6015\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6015|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/59/15293\" title=\"table 1\">",
"      Pneumococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/43/701\" title=\"table 2\">",
"      Comparison of pneumococcal conjugate and polysaccharide vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/13/6364\" title=\"table 3\">",
"      High risk conditions for invasive pneumococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/63/21501\" title=\"table 4\">",
"      PCV and PPSV23 in high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/60/24523\" title=\"table 5\">",
"      PPSV23 schedule for high-risk children older than two years",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35913?source=related_link\">",
"      Cochlear implant infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23143?source=related_link\">",
"      Microbiology and pathogenesis of Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_38_13927="Dinoprostone: Drug information";
var content_f13_38_13927=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dinoprostone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/10/32932?source=see_link\">",
"    see \"Dinoprostone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cervidil&reg;;",
"     </li>",
"     <li>",
"      Prepidil&reg;;",
"     </li>",
"     <li>",
"      Prostin E",
"      <sub>",
"       2",
"      </sub>",
"      &reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cervidil&reg;;",
"     </li>",
"     <li>",
"      Prepidil&reg;;",
"     </li>",
"     <li>",
"      Prostin E",
"      <sub>",
"       2",
"      </sub>",
"      &reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Abortifacient;",
"     </li>",
"     <li>",
"      Prostaglandin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Abortifacient:",
"     </b>",
"     <i>",
"      Vaginal suppository:",
"     </i>",
"     Insert 20 mg (1 suppository) high in vagina, repeat at 3- to 5-hour intervals until abortion occurs; continued administration for longer than 2 days is not advisable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical ripening:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Endocervical gel:",
"     </i>",
"     Using catheter supplied with gel, insert 0.5 mg into the cervical canal.  May repeat every 6 hours if needed. Maximum cumulative dose: 1.5 mg/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Tablet (oral) (Canadian availability):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Induction: Initial: 0.5 mg and then repeat 0.5 mg dose 1 hour later; may give additional 0.5 mg dose on an hourly basis as needed for satisfactory uterine response. Maintain patient at the lowest effective dose.",
"     <b>",
"      Note:",
"     </b>",
"     Failure to induce regular contractions after 8 hours indicates failed induction and alternative management of patient should be considered. If patient vomits an intact tablet during therapy repeat dose. If patient vomits intact tablets following 2 successive doses, withhold therapy until next scheduled dose. If patient vomits a partial tablet or if no tablet is visible, continue at next regularly scheduled dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Parity &ge;2 times or Bishop Score of &ge;6: Administer 0.5 mg hourly throughout induction (discontinue hourly dose for excessive uterine activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nulliparous or multiparous and resistant to induction (Bishop Score &lt;6): If inadequate response after 2 hours of therapy may increase dose in 0.5 mg increments at hourly intervals up to a maximum single dose of 1.5 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance of labor: 0.5 mg dose hourly; may occasionally withhold hourly dose to assess need for further dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Vaginal gel (Canadian labeling):",
"     </i>",
"     Initial: Using prefilled syringe, insert 1 mg into the posterior fornix of the vaginal canal; may give 1 additional dose of 1-2 mg 6 hours later if needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Vaginal insert:",
"     </i>",
"     Insert 10 mg transversely into the posterior fornix of the vagina (to be removed at the onset of active labor or after 12 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3946482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females of reproductive age: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, endocervical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prepidil&reg;: 0.5 mg/3 g (3 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Insert, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervidil&reg;: 10 mg (1s) [releases 0.3 mg/hour]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prostin E",
"     <sub>",
"      2",
"     </sub>",
"     &reg;: 20 mg (5s)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15671160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prostin E",
"     <sub>",
"      2",
"     </sub>",
"     &reg;: 1 mg/3 g (3 g), 2 mg/3 g (3 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prostin E",
"     <sub>",
"      2",
"     </sub>",
"     &reg;: 0.5 mg [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F160945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocervical gel: Bring to room temperature just prior to use. Do not force the warming process (eg, water bath, microwave). Avoid contact with skin while handling; wash hands thoroughly with soap and water after administration. For cervical ripening, patient should be supine in the dorsal position. The appropriate catheter length should be based on degree of effacement; 20 mm for no effacement; 10 mm if 50% effaced. Patient should remain supine for 15-30 minutes following administration. The manufacturer recommends waiting 6-12 hours after dinoprostone gel administration before initiating oxytocin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet (oral) (Canadian availability): Administer with small amount of water. Use of oxytocin should be avoided until &ge;1 hour after administration of the last oral tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal gel: (Canadian availability): Using prefilled syringe, dose is placed in the posterior fornix of the vagina. Patient should remain in lateral or supine position for 30 minutes to prevent leakage. Syringe contains overfill. Syringe is for single use only. Use of oxytocin should be avoided for 12-24 hours after administration of vaginal gel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal insert: One vaginal insert is placed transversely in the posterior fornix of the vagina immediately after removal from its foil package. Patients should remain in the recumbent position for 2 hours after insertion, but thereafter may be ambulatory. Do not use without retrieval system. Product does not need warmed prior to use. A water miscible lubricant may be used to facilitate insertion (avoid excessive use of lubricant). Ensure complete removal of system at completion of therapy. The manufacturer recommends waiting &ge;30 minutes after removing the dinoprostone vaginal insert before initiating oxytocin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal suppository: Insert high into vagina after removal from its foil package. Bring to room temperature just prior to use. Patient should remain supine for 10 minutes following insertion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocervical gel (Prepidil&reg;): Promote cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppositories (Prostin E",
"     <sub>",
"      2",
"     </sub>",
"     &reg;): Terminate pregnancy from 12th through 20th week of gestation; evacuate uterus in cases of missed abortion or intrauterine fetal death up to 28 weeks of gestation; manage benign hydatidiform mole (nonmetastatic gestational trophoblastic disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet (oral) (Prostin E",
"     <sub>",
"      2",
"     </sub>",
"     &reg;; Canadian availability): Elective induction of labor; when indications for induction of labor exist (eg, premature rupture of amniotic membranes, toxemia of pregnancy, Rh incompatibility, diabetes mellitus, hypertension, postmaturity, intrauterine death or fetal growth retardation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal gel (Prostin E",
"     <sub>",
"      2",
"     </sub>",
"     &reg;; Canadian availability): Induction of labor in patients at or near term with singleton pregnancy, vertex presentation, and favorable induction features",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal insert (Cervidil&reg;): Initiation and/or continuation of cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labor",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cervidil brand name for dinoprostone [U.S., Canada, Australia, New Zealand], but also the brand name for gemeprost [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endocervical gel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: GI upset (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Abnormal uterine contractions (7%), warm feeling in vagina (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Amnionitis, anaphylactoid syndrome of pregnancy (amniotic fluid embolism), postpartum DIC, premature rupture of membranes, uterine rupture (with intracervical administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Suppository:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest pain, chest tightness, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, shivering, tension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash, skin discoloration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast tenderness, endometritis, hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dehydration, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Uterine rupture, urinary retention, vaginal pain, vaginismus, vaginitis, vulvitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, backache, joint inflammation/pain (new or exacerbated), leg cramps (nocturnal), muscle cramp/pain, myalgia, paresthesia, stiff neck, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision, eye pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hearing impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, laryngitis, pharyngitis, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: MI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Tablets (oral) (Canadian availability):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Vomiting (with or without nausea/diarrhea): 21% to 50% (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%: Genitourinary: Uterine hypertonus (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1%: Bronchospasm, chills, dizziness, dyspnea, fever, flushing, headache, hiccups, hyper-/hypotension, postpartum hemorrhage, rash, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Transient vasovagal symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Abnormal uterine contractions, placental abruption, rapid cervical dilation, uterine rupture",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Asthma, pulmonary amniotic fluid embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions including anaphylaxis, anaphylactic shock, and nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports: DIC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaginal gel (Canadian availability):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%: Genitourinary: Uterine hypercontractility (3%), failed induction (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Abnormal uterine contractions, uterine rupture, warm feeling in vagina",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions including anaphylaxis, anaphylactic shock, and nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Postmarketing and/or case reports: DIC",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaginal insert:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%: Genitourinary: Uterine hyperstimulation",
"     <i>",
"      without",
"     </i>",
"     fetal distress (2% to 5%), uterine hyperstimulation",
"     <i>",
"      with",
"     </i>",
"     fetal distress (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid syndrome of pregnancy (amniotic fluid embolism), postpartum DIC, hypersensitivity reactions, hypotension, uterine rupture",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Generally, labor induction is contraindicated whenever spontaneous labor or vaginal delivery is contraindicated (ACOG 2009); manufacturer specific contraindications are listed by dosage form.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     All dosage forms: Hypersensitivity to prostaglandins or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocervical gel: Patients in whom oxytocic drugs are contraindicated; history of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; fetal distress when delivery is not imminent; unexplained vaginal bleeding during this pregnancy; history of difficult labor and/or traumatic delivery; &ge;6 previous term pregnancies with nonvertex presentation; hyperactive or hypertonic uterine patterns; obstetric emergencies when surgical intervention would be favorable; placenta previa; when vaginal delivery is not indicated (eg, vasa previa, active herpes genitalia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling: Additional contraindications (not in U.S. labeling):",
"     </i>",
"     History of epilepsy; fetal malpresentation; overdistention of the uterus (multiple pregnancies, polyhydramnios); ruptured amniotic membranes or suspected chorioamnionitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository: Acute pelvic inflammatory disease; active cardiac, pulmonary, renal, or hepatic disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet (oral) (Canadian availability; not available in the U.S.): Active cardiac, pulmonary, renal or hepatic disease; simultaneous use with other oxytocics; history of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; history of difficult labor and/or traumatic delivery; &ge;6 pregnancies; suspected or clinically evident pre-existing fetal distress; overdistention of the uterus (multiple pregnancy, polyhydramnios); pre-existing uterine hypertonus; situations where a responsible physician is unavailable; engagement of head not taken place; unexplained vaginal bleeding during this pregnancy; fetal malpresentation; gynecological, obstetrical or medical conditions that preclude vaginal delivery; pregnancy complicated by abnormal position of the placenta or umbilical cord; history of or existing pelvic inflammatory disease unless adequately treated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal gel (Canadian availability; not available in the U.S.): Active cardiac, pulmonary, renal or hepatic disease; simultaneous use with other oxytocics; history of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; history of difficult labor and/or traumatic delivery; &ge;6 term pregnancies; suspected or clinically evident pre-existing fetal distress; overdistention of the uterus (multiple pregnancy, polyhydramnios); pre-existing uterine hypertonus; situations where a responsible physician is unavailable; engagement of head not taken place; unexplained vaginal bleeding during this pregnancy; fetal malpresentation; gynecological, obstetrical or medical conditions that preclude vaginal delivery; pregnancy complicated by abnormal position of the placenta or umbilical cord; history of or existing pelvic inflammatory disease unless adequately treated; ruptured amniotic membranes or suspected chorioamnionitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal insert: Patients in whom oxytocic drugs are contraindicated;  history of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; fetal distress when delivery is not imminent; unexplained vaginal bleeding during this pregnancy; patients already receiving I.V. oxytocic drugs; &ge;6 previous term pregnancies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling: Additional contraindications (not in U.S. labeling):",
"     </i>",
"     Placenta previa; history of difficult labor and/or traumatic delivery; overdistention of the uterus (multiple pregnancies, polyhydramnios); fetal malpresentation; history of uncontrolled epilepsy; history of or existing pelvic inflammatory disease unless adequately treated",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid syndrome of pregnancy: Intracervical placement of endocervical gel, vaginal gel or vaginal insert may lead to anaphylactoid syndrome of pregnancy (rare).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Disseminated intravascular coagulation (DIC): Postpartum DIC has been reported following dinoprostone for labor induction. Risk may be increased in women &ge;30 years of age, gestation age &gt;40 weeks, or women with pregnancy complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use caution in patients with cardiovascular disease; manufacturer labeling for some dosage forms (eg, suppository, tablet, vaginal gel)  contraindicate use in active cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use with caution in patients with epilepsy; Canadian labeling (depending on dosage form) either contraindicates use in patients with epilepsy or recommends avoiding use unless seizures are adequately controlled.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use caution in patients with glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with hepatic impairment; manufacturer labeling for some dosage forms (eg, suppository, tablet, vaginal gel) contraindicate use in active hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary disease: Use caution in patients with a history of asthma; manufacturer labeling for some dosage forms (eg, suppository, tablet, vaginal gel) contraindicate use with active pulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use caution in patients with renal impairment; manufacturer labeling for some dosage forms (eg, suppository, tablet, vaginal gel) contraindicate use in active renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocervical gel: Use caution with ruptured membranes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suppository: When used for termination of pregnancy, dinoprostone is not considered feticidal, but is used to terminate pregnancy due to its ability to stimulate uterine contractions; do not use if fetus has reached the stage of viability. Transient pyrexia and decreased blood pressure may be observed with treatment. Use caution with history of hypotension or hypertension; cardiovascular disease; anemia; jaundice; diabetes; compromised uteri; cervicitis, endocervical infections or acute vaginitis. Measures should be taken to ensure complete abortion. Commercially available suppositories should not be used for extemporaneous preparation of any other dosage form of drug. Do not use for cervical ripening or other indications in patients with term pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal gel: Canadian availability (not available in U.S.): For intravaginal use only; not for intracervical use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal insert: Use caution with ruptured membranes; nonvertex or nonsingleton pregnancy or previous uterine hypertony. Must be removed prior to administration of oxytocin, in case of hyperstimulation or if labor begins, fetal distress, maternal distress (eg, hypotension, nausea, tachycardia, vomiting), and prior to amniotomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel:",
"     <b>",
"      [U.S. Boxed Warning]: Dinoprostone should be used only by medically-trained personnel in a hospital.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbetocin: Dinoprostone may enhance the therapeutic effect of Carbetocin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxytocin: Dinoprostone may enhance the therapeutic effect of Oxytocin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3946439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skeletal anomalies and embryotoxicity have been observed in animal reproduction studies. Although these effects would not be expected in humans when administered after the period of organogenesis, a sustained increase in uterine tone may have increased risks of adverse events to the fetus.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fetal distress without corresponding maternal uterine hyperstimulation was observed in 3% to 4% of infants exposed to Cervidil&reg;",
"     <i>",
"      in utero.",
"     </i>",
"     No adverse effects on physical or psychomotor function were observed in a 3 year follow-up study of exposed infants. Abnormal fetal heart rates were observed in 17% of infants exposed to Prepidil&reg; gel",
"     <i>",
"      in utero.",
"     </i>",
"     Deceleration, intrauterine fetal sepsis, fetal depression and fetal acidosis have also been reported with administration of the endocervical gel. Still births, abnormal fetal heart rate and fetal distress have been reported with administration of Prostin E",
"     <sub>",
"      2",
"     </sub>",
"     &reg; vaginal gel and oral tablets (Canadian availability).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for termination of pregnancy, dinoprostone is not considered feticidal, but is used to terminate pregnancy due to its ability to stimulate uterine contractions; do not use if fetus has reached the stage of viability.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F160967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3946441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous PGE",
"     <sub>",
"      2",
"     </sub>",
"     can be detected in breast milk. High levels have been associated with diarrhea in nursing infants.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Prepidil Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mg/3 g (3 g): $400.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      INST",
"     </b>",
"     (Cervidil Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $256.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Prostin E2 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (5): $7708.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3946483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, insert: Fetal heart rate, uterine activity, progression of cervical dilation and effacement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suppository: Confirmation of fetal death",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cervidil (AU, NZ);",
"     </li>",
"     <li>",
"      Cerviprime (IN, PH);",
"     </li>",
"     <li>",
"      Cerviprost (AT, RU);",
"     </li>",
"     <li>",
"      Minprostin (NO, SE);",
"     </li>",
"     <li>",
"      Minprostin E(2) (DE, DK);",
"     </li>",
"     <li>",
"      Prandin E2 (ZA);",
"     </li>",
"     <li>",
"      Prepidil (AE, AT, BE, BG, BH, CO, CY, CZ, EG, ES, FR, HN, HR, HU, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MY, NL, OM, PK, PL, QA, SA, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Primiprost (IN);",
"     </li>",
"     <li>",
"      Prolisina E2 (AR);",
"     </li>",
"     <li>",
"      Propess (FI, FR, IL, SE);",
"     </li>",
"     <li>",
"      Propess Vag SR (KP);",
"     </li>",
"     <li>",
"      Prostaglandina E2 (ES);",
"     </li>",
"     <li>",
"      Prostarmon E (TW);",
"     </li>",
"     <li>",
"      Prostenon (EE);",
"     </li>",
"     <li>",
"      Prostin E2 (AE, AT, BE, BF, BG, BH, BJ, CH, CI, CY, EG, ET, GB, GH, GM, GN, GR, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PT, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Prostin E2 Vaginal Cream (AU);",
"     </li>",
"     <li>",
"      Prostin E2 Vaginal Gel (NZ);",
"     </li>",
"     <li>",
"      Prostin VR (LU);",
"     </li>",
"     <li>",
"      Prostine (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dinoprostone (prostaglandin E",
"     <sub>",
"      2",
"     </sub>",
"     ) is an endogenous hormone found in low concentrations in most tissues of the body. When administered as an abortifacient, it stimulates uterine contractions similar to those seen during natural labor. When administered for labor induction, it relaxes the smooth muscle of the cervix allowing dilation and passage of the fetus through the birth canal.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (uterine contractions): Vaginal suppository: Within 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Vaginal insert: 0.3 mg/hour over 12 hours; Vaginal suppository: Up to 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Vaginal suppository: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Metabolized in the lungs; forms metabolites which are further metabolized in the liver and kidney",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Endocervical gel: 30-45 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine; feces (small amounts)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins - Obstetrics, \"ACOG Practice Bulletin No.107: Induction of Labor,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2009, 114(2 Pt 1):386-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/38/13927/abstract-text/19623003/pubmed\" id=\"19623003\" target=\"_blank\">",
"        19623003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cusick W, Leuci D, Viscarello RR, et al, &ldquo;Anaphylactoid Syndrome of  Pregnancy After Intracervical Dinoprostone for Cervical Ripening: A Report of 3 Cases,&rdquo;",
"      <i>",
"       J Reprod Med",
"      </i>",
"      , 2005, 50(3):225-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/38/13927/abstract-text/15841940/pubmed\" id=\"15841940\" target=\"_blank\">",
"        15841940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Novakov A, Segedi D, Milasinovic L, et al, &ldquo;Induction of Labor by Endocervical Application of Prostaglandins and Intravenous Infusion of Oxytocin in Post-term Pregnancy,&rdquo;",
"      <i>",
"       Med Pregl",
"      </i>",
"      , 1998, 51(9-10):419-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/38/13927/abstract-text/9863332/pubmed\" id=\"9863332\" target=\"_blank\">",
"        9863332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9368 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13927=[""].join("\n");
var outline_f13_38_13927=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708703\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160960\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160961\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161000\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160964\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3946482\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160943\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671160\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160929\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160945\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160944\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161006\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160998\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160948\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160933\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299208\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160938\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160940\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3946439\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160967\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3946441\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323113\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3946483\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160951\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160932\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160947\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9368\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9368|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/10/32932?source=related_link\">",
"      Dinoprostone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_38_13928="Pathophysiology of reflux esophagitis";
var content_f13_38_13928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of reflux esophagitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13928/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13928/contributors\">",
"     Peter J Kahrilas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13928/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13928/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13928/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/38/13928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An essential concept in the pathogenesis of gastroesophageal reflux disease (GERD) is that the extent of symptoms and of mucosal injury is proportional to the frequency of reflux events, the duration of mucosal acidification, and the caustic potency of refluxed fluid. The integrity of the esophageal mucosa in normal individuals reflects the balance between injurious forces (acid reflux, potency of refluxate) and defensive forces (esophageal acid clearance, mucosal integrity). For one or more reasons, this balance becomes impaired in patients who develop GERD.",
"   </p>",
"   <p>",
"    The pathophysiology of GERD will be reviewed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISMS OF REFLUX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary event in the pathogenesis of gastroesophageal reflux disease (GERD) is movement of gastric juice from the stomach into the esophagus. The antireflux barrier at the gastroesophageal junction is anatomically and physiologically complex and vulnerable to several potential mechanisms of reflux. The three dominant pathophysiologic mechanisms causing gastroesophageal junction incompetence are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transient lower esophageal sphincter relaxations (tLESRs)",
"     </li>",
"     <li>",
"      A hypotensive lower esophageal sphincter (LES)",
"     </li>",
"     <li>",
"      Anatomic disruption of the gastroesophageal junction, often associated with a hiatal hernia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although examples of each have been documented in mechanistic studies, their relative importance continues to be debated. The evolving concept is that the dominant mechanism varies as a function of disease severity with tLESRs predominating with mild disease and mechanisms associated with a hiatus hernia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a weak sphincter predominating with more severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/1\">",
"     1",
"    </a>",
"    ]. The relatively recent availability of esophageal impedance testing, which can detect reflux irrespective of pH, discern reflux of gas from liquid, and determine the distribution of refluxate, will likely help determine the impact of these variables on the clinical features of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Transient lower esophageal sphincter relaxations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient lower esophageal sphincter relaxations account for essentially all reflux events in individuals with a normal LES pressure at the time of reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. There are several major differences between tLESRs and swallow-induced LES relaxation: tLESRs occur without an associated pharyngeal contraction, are unaccompanied by esophageal peristalsis, and persist for longer periods (&gt;10 sec) than do swallow-induced LES relaxations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has become increasingly clear that tLESRs are the physiological mechanism of belching. The frequency of tLESRs is greatly increased by distension of the stomach or by assuming an upright posture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, a tLESR is an integrated motor response involving not only LES relaxation, but also crural diaphragmatic inhibition, esophageal shortening by contraction of its longitudinal muscle, and contraction of the costal diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. That tLESRs are an active, vagally mediated reflex, rather than the result of forceful gastric distention, was demonstrated by both a combined",
"    <span class=\"nowrap\">",
"     endoscopic/manometric",
"    </span>",
"    study and a combined",
"    <span class=\"nowrap\">",
"     manometric/fluoroscopic",
"    </span>",
"    study showing that sphincter relaxation (evident manometrically) always preceded actual esophagogastric junction opening [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One hypothesis is that a primary determinant of reflux disease is not an increased number of tLESRs, rather an increased proportion of tLESRs that are associated with acid reflux as opposed to only gas venting. Such a progression could be caused by increased compliance of the EGJ as a consequence of",
"    <span class=\"nowrap\">",
"     weakening/dilatation",
"    </span>",
"    of the diaphragmatic hiatus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/13\">",
"     13",
"    </a>",
"    ]. Increased compliance leads to an increased luminal cross-sectional area during opening that in turn results in an increased volume of reflux and a reduced ability to limit refluxate to gas. Different investigators have documented acid reflux during as many as 93 percent or as few as 9 to 15 percent of tLESRs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/7,14\">",
"     7,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal and human experiments have demonstrated that tLESRs can be inhibited by gamma aminobutyric acid receptor type B agonists (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    and lesogaberan), suggesting a potential new pharmacological target to the treatment of GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical management of gastroesophageal reflux disease in adults\", section on 'Adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypotensive lower esophageal sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LES is a 3 to 4 cm long segment of tonically contracted smooth muscle at the distal end of the esophagus. LES tonic contraction is a property of both the muscle itself and of its extrinsic innervation. Normal resting tone of the LES varies from 10 to 30 mmHg, being least in the post-cibal period and greatest at night [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only a minority of individuals with GERD have a grossly hypotensive LES (&lt;10 mmHg) when determined during fasting measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/20\">",
"     20",
"    </a>",
"    ]. There are, however, a host of factors that can reduce LES pressure: gastric distension, cholecystokinin, various foods (fat, chocolate, caffeine, alcohol), smoking, and many drugs. Thus, many patients have periods of gross LES hypotension as a result of foods, drugs, or habits.",
"   </p>",
"   <p>",
"    Gastroesophageal reflux can occur with diminished LES pressure either by strain-induced reflux or free reflux:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strain-induced reflux occurs when a hypotensive LES is overcome and \"blown open\" by an abrupt increase of intraabdominal pressure. Manometric data suggest that stress reflux is relatively unusual unless the LES pressure is less than 4 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/21\">",
"       21",
"      </a>",
"      ]. However, these studies were somewhat limited by the required instrumentation and may not be entirely reflective of normal ambulatory circumstances (see below).",
"     </li>",
"     <li>",
"      During free reflux a fall in intraesophageal pH occurs without identifiable change in either intragastric or LES pressure. Free reflux is observed only when LES pressure is within 0 to 4 mmHg of intragastric pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hiatal hernia and the diaphragmatic sphincter",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diaphragm as well as the LES contributes to gastroesophageal sphincter competence, making it more accurate to think of the composite as esophagogastric junction (EGJ) pressure. Recordings of LES pressure usually exhibit inspiratory increases as a result of contraction of the diaphragmatic crus that encircles the LES [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/22\">",
"     22",
"    </a>",
"    ]. Observations of the antireflux mechanism during maneuvers such as leg raising and abdominal compression suggest a \"pinchcock\" effect of crural contraction that augments the antireflux barrier. The crural diaphragmatic component of EGJ pressure is most relevant in patients with hiatal hernia, in whom this component may be impaired.",
"   </p>",
"   <p>",
"    However, a study examining the correlation between GERD, hiatus hernia, LES pressure, and crural diaphragm function as quantified by the magnitude of EGJ pressure augmentation during inspiration found that function of the crural diaphragm was most strongly correlated with GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/23\">",
"     23",
"    </a>",
"    ]. Furthermore, the associations between GERD and hiatus hernia or LES pressure no longer achieved statistical significance after considering the effect of inspiratory augmentation in multivariate analysis, suggesting both effects were largely mediated by associated crural diaphragm dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The susceptibility to reflux under circumstances of abrupt increases of intraabdominal pressure (eg, during bending or coughing) depends upon both the instantaneous LES pressure and the diaphragmatic sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with hiatus hernia can have progressive disruption of the diaphragmatic sphincter. Therefore, although neither condition (hiatus hernia or hypotensive LES) alone results in severe incompetence; the two conditions interact with each other in more than an additive fashion. The severity of esophagitis correlates with the size of the hiatal hernia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/25\">",
"     25",
"    </a>",
"    ]. Two other factors also appear to be important in patients with reflux associated with a hiatus hernia. A hiatus hernia is associated with a reduced threshold for eliciting tLESRs in response to gastric distension [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/26\">",
"     26",
"    </a>",
"    ]. It is also associated with malfunction of the gastroesophageal barrier during periods of low LES pressure, during normal swallow-associated LES relaxation, and during deep inspiration or straining [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=see_link\">",
"     \"Hiatus hernia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a risk factor for GERD, erosive esophagitis, and esophageal adenocarcinoma. The mechanisms by which this occurs are incompletely understood.",
"   </p>",
"   <p>",
"    Several studies have evaluated the relationship between obesity and GERD but comparison among them is limited by variable definitions used and differences in study design [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/28\">",
"     28",
"    </a>",
"    ]. One of the most comprehensive studies included a total of 285 patients in whom anthropometric variables were correlated with findings on manometry [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/29\">",
"     29",
"    </a>",
"    ]. There was a significant correlation of body mass index and waist circumference with intragastric pressure and the gastroesophageal pressure gradient. Obesity was also associated with disruption of the esophagogastric junction leading to a hiatal hernia and increased esophageal acid exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Obesity, particularly abdominal obesity, has also been associated with increased reflux symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extending on these findings, another report found obesity to be associated with both an increased frequency of tLESRs and an increased proportion of tLESRs associated with acid reflux during the postprandial period in subjects without hiatus hernia or clinical evidence of GERD. These findings suggest that LES dysfunction might be an important mediator of the pathogenesis of obesity-related GERD [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether weight loss can reverse obesity-related changes is unclear. In a study involving questionnaires obtained from 10,545 women, body mass index was associated with symptoms of GERD in a dose-response relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/34\">",
"     34",
"    </a>",
"    ]. Even moderate weight gain in women of normal weight was potentially associated with exacerbation of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy and exogenous estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heartburn occurs in 30 to 50 percent of pregnancies. It is due to both mechanical and intrinsic factors that adversely affect lower esophageal sphincter tone. Estrogen replacement therapy in postmenopausal women also appears to modestly increase the risk of heartburn [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=see_link\">",
"     \"Maternal gastrointestinal tract adaptation to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ESOPHAGEAL ACID CLEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following reflux, the period that the esophageal pH remains less than 4 is called the acid clearance time. Esophageal acid clearance begins with emptying the refluxed fluid from the esophagus by peristalsis and is completed by titration of the residual acid by swallowed saliva (",
"    <a class=\"graphic graphic_figure graphicRef72899 \" href=\"UTD.htm?13/40/13952\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/36\">",
"     36",
"    </a>",
"    ]. Approximately 7 mL of saliva will neutralize 1 mL of 0.1 N HCl, with 50 percent of the neutralizing capacity being attributable to salivary bicarbonate. The normal rate of salivation is about 0.5",
"    <span class=\"nowrap\">",
"     mL/min;",
"    </span>",
"    maneuvers that increase salivation (eg, oral lozenges or gum chewing) will hasten acid clearance while circumstances of diminished salivation (eg, sleep) will delay it.",
"   </p>",
"   <p>",
"    Prolongation of esophageal acid clearance occurs in about one-half of patients with esophagitis. A review of a large data set of 24-hour esophageal pH recordings suggested that individuals with known hiatal hernias tended to have the most prolonged recumbent acid clearance times [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/37\">",
"     37",
"    </a>",
"    ]. The two major causes of this problem are impaired esophageal emptying and impaired salivary function. Abnormal acid clearance improves with an erect posture, suggesting that gravity compensates for impaired fluid emptying.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Esophageal emptying in GERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two mechanisms of impaired esophageal emptying have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peristaltic dysfunction, resulting in either failed or hypotensive (&lt;30 mmHg) peristaltic contractions [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/38\">",
"       38",
"      </a>",
"      ]. Peristaltic dysfunction becomes more common with increasing severity of esophagitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/20\">",
"       20",
"      </a>",
"      ]. Whether peristaltic dysfunction associated with peptic esophagitis is reversible is disputed. Most likely, acute dysfunction associated with active esophagitis is partially reversible, while chronic dysfunction associated with stricturing or extensive fibrosis is not.",
"     </li>",
"     <li>",
"      \"Re-reflux\" associated with hiatal hernias which also impairs esophageal emptying [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. Scintiscanning and pH recording concurrent with fluoroscopy demonstrate \"re-reflux\" from the hernia sac during swallowing. This occurs only with \"nonreducing\" hernias that are evident between swallows and during peristalsis-induced esophageal shortening. In one report, for example, retrograde flow or \"re-reflux\" was seen with almost 50 percent of test swallows in patients with nonreducing hernias, impairing both esophageal emptying and esophageal acid clearance [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential for re-reflux may be aggravated by the presence of an \"acid pocket\" in the most proximal gastric cardia that escapes the buffering effects of food and remains highly acidic during the postprandial period [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/41\">",
"     41",
"    </a>",
"    ]. The net result is much greater acid exposure just above the squamocolumnar junction compared to 5 cm proximal to it, likely explaining the propensity of the distal area to develop mucosal erosions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Salivary function in GERD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced salivation or diminished salivary neutralizing capacity also prolongs acid clearance. Diminished salivation during sleep, for example, explains why reflux events during sleep or immediately prior to going to sleep are associated with markedly prolonged acid clearance times. In addition, chronic xerostomia is associated with prolonged esophageal acid exposure and esophagitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the only large scale analysis of salivary function in GERD found no difference between the resting salivary function of the esophagitis patients and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cigarette smokers have prolonged esophageal acid clearance times due to hyposalivation. In one report, for example, smokers without symptoms of reflux disease were found to have acid clearance times 50 percent longer than those of nonsmokers; furthermore, the salivary titratable base content of the smokers was only 60 percent of the age-matched nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MECHANISMS OF AND DEFENSES AGAINST ESOPHAGEAL INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of esophagitis in gastroesophageal reflux disease (GERD) on a cellular level is due to hydrogen ion diffusion into the mucosa, leading to cellular acidification and necrosis. As noted above, reflux, impaired esophageal emptying, and diminished salivary function contribute to increased exposure of the esophagus to acid. In contrast, esophagitis is less clearly related to increased gastric acid secretion in GERD patients. This was demonstrated in a study which compared gastric acid and pepsin secretion in 115 patients with endoscopically-graded esophagitis to 508 age- and disease-matched controls without esophagitis; there were no differences between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/47\">",
"     47",
"    </a>",
"    ]. A caveat to this is that reduced acid secretion as can be seen with chronic",
"    <em>",
"     H. pylori",
"    </em>",
"    gastritis may be somewhat protective against GERD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9959?source=see_link\">",
"     \"Helicobacter pylori and gastroesophageal reflux disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pepsin, bile acids, trypsin, and food hyperosmolality increase the susceptibility of the esophageal mucosa to acid injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/48\">",
"     48",
"    </a>",
"    ]. Pepsin and bile acids have been subjected to the most scrutiny. At pH 2, pepsin disrupts the histologic integrity of the mucosal barrier, increases hydrogen ion permeability, and causes hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, an esophagus exposed to a pepsin perfusate at pH 7.5 followed by a solution at pH 2 without pepsin shows minimal mucosal disruption or changes in permeability. Thus, pepsin's ability to cause mucosal injury is pH dependent, with maximal enzyme activity below pH 3.",
"   </p>",
"   <p>",
"    Bile acids have been implicated in the development of esophagitis primarily in patients with increased duodenogastric reflux following gastric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/50\">",
"     50",
"    </a>",
"    ]. However, bile acids are not as important as acid and pepsin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Epithelial defense",
"    </span>",
"    &nbsp;&mdash;&nbsp;The esophageal mucosa possesses several morphologic and physiologic defenses against cellular acidification. Conceptually, epithelial defenses can be subdivided into preepithelial, epithelial, and postepithelial factors [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preepithelial defenses (surface mucous and bicarbonate that maintain a significant pH gradient between lumen and cell surface) are poorly developed in the esophagus; as a result, the pH gradient in the mucus layer is minimal or nil [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although the esophageal epithelium contains a few submucosal glands that secrete bicarbonate into the submucosa, mucosa, and lumen [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/53\">",
"       53",
"      </a>",
"      ], the main defense against acid injury is the epithelial barrier itself. The esophageal mucosa is a relatively \"tight\" epithelium, resistant to ionic movements at the intercellular as well as the cellular level because of the tight junctions and the lipid rich matrix in the intercellular space [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/54\">",
"       54",
"      </a>",
"      ]. This mucosa can retard hydrogen ion penetration in the face of ion gradients of greater than 5 pH units.",
"      <br/>",
"      <br/>",
"      The importance of tight junctions has been demonstrated by the luminal and serosal application of low molecular weight markers of paracellular permeability. When applied luminally, the paracellular movement of these markers was restricted to the first few layers of the stratum corneum by tight junctions; when applied serosally, they permeated freely through the basal cell and stratum spinosum layers and were retarded only within seven to nine cell layers of the lumen [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/54\">",
"       54",
"      </a>",
"      ]. These observations illustrate the vulnerability of the esophageal mucosa to injury once the superficial cell layers have been lost. A histomorphometric correlate of increased paracellular permeability is the presence of dilated intercellular spaces, evident in transmission electron microscopy. Detailed analyses suggest this to be a sensitive and reversible marker for a reflux injured esophagus [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Further defense of the esophageal epithelium is provided by hydrogen ion extrusion [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/56\">",
"       56",
"      </a>",
"      ]. Two pH-activated acid extruding processes are located on esophageal membranes: a",
"      <span class=\"nowrap\">",
"       Na/H",
"      </span>",
"      exchanger; and a sodium dependent",
"      <span class=\"nowrap\">",
"       Cl/HCO3",
"      </span>",
"      exchanger. Once extruded, the hydrogen ions are buffered by extracellular bicarbonate in equilibrium with the blood. Thus, blood flow is the main postepithelial defense, interacting with epithelial factors to protect against acid injury. In addition to providing nutrients for metabolic activity, blood flow increases in response to luminal acid, delivering more bicarbonate to the intercellular space [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Finally, when the epithelial cells are no longer able to maintain intracellular pH, they lose the ability to volume regulate and cellular edema ensues. Esophageal acid injury also stimulates cell proliferation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/57\">",
"       57",
"      </a>",
"      ], which is observed in biopsy specimens as thickening of the basal cell layer of the epithelium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Esophageal hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite careful evaluation, some patients who have typical reflux-like symptoms do not have pathologic reflux documented by endoscopy or 24-hour pH studies. The symptoms of these hypersensitive patients are similar to those with GERD. This was illustrated in a study that compared 70 patients whose initial pH study demonstrated normal acid exposure but had symptoms of GERD with 58 patients found to have excess reflux on 24-hour pH studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/58\">",
"     58",
"    </a>",
"    ]. During follow-up of 4.4 to 6.5 years, a similar proportion of patients continued to have symptoms in both groups (87 versus 79 percent, respectively). Furthermore, approximately 60 percent of patients in both groups regularly continued take medications for GERD.",
"   </p>",
"   <p>",
"    The cause of heartburn in patients with normal esophageal acid exposure is uncertain but may be related to heightened esophageal sensitivity (also called visceral hyperalgesia). This hypothesis was evaluated in a study of 152 patients with chronic heartburn who underwent endoscopy, esophageal manometry, 24-hour pH monitoring, intraesophageal balloon distension, and Bernstein testing (infusion of 0.1N HCl or saline in the esophagus in a blinded fashion) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13928/abstract/59\">",
"     59",
"    </a>",
"    ]. Normal esophageal acid exposure (less than 6 percent in a 24-hour study) was observed in 43 percent of patients. Of these patients, 64 percent had normal lower esophageal sphincter pressure, and 79 percent had a normal endoscopy. However, 89 percent developed heartburn during Bernstein testing, and 52 percent had lower pain thresholds for esophageal balloon distension than normal values in healthy volunteers.",
"   </p>",
"   <p>",
"    These results suggest that heartburn may be due to esophageal hypersensitivity to normal acid exposure or other stimuli in some patients. This is analogous to the visceral hyperalgesia described in a variety of other disorders including noncardiac chest pain, functional dyspepsia, and irritable bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=see_link\">",
"     \"Chest pain of esophageal origin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     HELICOBACTER PYLORI",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    ) is an important risk factor for the development of peptic ulcer disease, gastric adenocarcinoma, and primary B cell lymphoma of the stomach. A possible role for",
"    <em>",
"     H. pylori",
"    </em>",
"    in the pathogenesis of gastroesophageal reflux disease (GERD) has also been suggested in a growing number of studies. However, the link between GERD and",
"    <em>",
"     H. pylori",
"    </em>",
"    is complex and remains incompletely defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9959?source=see_link\">",
"     \"Helicobacter pylori and gastroesophageal reflux disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/33/37393?source=see_link\">",
"       \"Patient information: Hiatal hernia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450877177\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The integrity of the esophageal mucosa in normal individuals reflects the balance between injurious forces (acid reflux, potency of refluxate) and defensive forces (esophageal acid clearance, mucosal integrity). This balance is impaired in patients who develop GERD. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three dominant pathophysiologic mechanisms causing gastroesophageal junction incompetence are: transient lower esophageal sphincter relaxations (tLESRs), a hypotensive lower esophageal sphincter (LES), and anatomic disruption of the gastroesophageal junction, often associated with a hiatal hernia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanisms of reflux'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      tLESRs occur without an associated pharyngeal contraction, are unaccompanied by esophageal peristalsis, and persist for longer periods (&gt;10 sec) than do swallow-induced LES relaxations. The primary determinant of reflux disease is an increased proportion of tLESRs that are associated with reflux of acid rather than gas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transient lower esophageal sphincter relaxations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A minority of individuals with GERD have a grossly hypotensive LES (&lt;10 mmHg) when determined during fasting measurements. However, many patients have periods of gross LES hypotension as a result of foods, drugs, or habits. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hypotensive lower esophageal sphincter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A hiatus hernia is associated with progressive disruption of the diaphragmatic sphincter resulting in increased susceptibility to reflux with abrupt increases of intraabdominal pressure. A hiatus hernia is also associated with a reduced threshold for eliciting tLESRs in response to gastric distension and malfunction of the gastroesophageal barrier during periods of low LES pressure, during normal swallow-associated LES relaxation, and during deep inspiration or straining. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hiatal hernia and the diaphragmatic sphincter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Esophageal acid clearance is accomplished with emptying the refluxed fluid from the esophagus by peristalsis and the titration of the residual acid by swallowed saliva. In patients with hiatus hernia, esophageal acid clearance may be impaired due to peristaltic dysfunction, resulting in either failed or hypotensive (&lt;30 mmHg) peristaltic contractions and re-reflux, which also impairs esophageal emptying.",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Esophageal acid clearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The esophageal mucosa possesses several morphologic and physiologic defenses against cellular acidification. Pepsin, bile acids, trypsin, and food hyperosmolality increase the susceptibility of the esophageal mucosa to acid injury. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mechanisms of and defenses against esophageal injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of heartburn in patients with normal esophageal acid exposure is uncertain, but may be related to heightened esophageal sensitivity (also called visceral hyperalgesia). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Esophageal hypersensitivity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/1\">",
"      Barham CP, Gotley DC, Mills A, Alderson D. Precipitating causes of acid reflux episodes in ambulant patients with gastro-oesophageal reflux disease. Gut 1995; 36:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/2\">",
"      Kahrilas PJ. Will impedence testing rewrite the book on GERD? Gastroenterology 2001; 120:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/3\">",
"      Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology 2001; 120:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/4\">",
"      Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/5\">",
"      Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980; 65:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/6\">",
"      Dodds WJ, Dent J, Hogan WJ, et al. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 1982; 307:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/7\">",
"      Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/8\">",
"      Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995; 268:G128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/9\">",
"      Martin CJ, Patrikios J, Dent J. Abolition of gas reflux and transient lower esophageal sphincter relaxation by vagal blockade in the dog. Gastroenterology 1986; 91:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/10\">",
"      Martin CJ, Dodds WJ, Liem HH, et al. Diaphragmatic contribution to gastroesophageal competence and reflux in dogs. Am J Physiol 1992; 263:G551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/11\">",
"      Massey BT, Simuncak C, LeCapitaine-Dana NJ, Pudur S. Transient lower esophageal sphincter relaxations do not result from passive opening of the cardia by gastric distention. Gastroenterology 2006; 130:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/12\">",
"      Pandolfino JE, Zhang QG, Ghosh SK, et al. Transient lower esophageal sphincter relaxations and reflux: mechanistic analysis using concurrent fluoroscopy and high-resolution manometry. Gastroenterology 2006; 131:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/13\">",
"      Pandolfino JE, Shi G, Trueworthy B, Kahrilas PJ. Esophagogastric junction opening during relaxation distinguishes nonhernia reflux patients, hernia patients, and normal subjects. Gastroenterology 2003; 125:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/14\">",
"      Kahrilas PJ, Gupta RR. Mechanisms of acid reflux associated with cigarette smoking. Gut 1990; 31:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/15\">",
"      Lehmann A, Antonsson M, Bremner-Danielsen M, et al. Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999; 117:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/16\">",
"      Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000; 118:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/17\">",
"      van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002; 16:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/18\">",
"      Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003; 52:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/19\">",
"      Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/20\">",
"      Kahrilas PJ, Dodds WJ, Hogan WJ, et al. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 1986; 91:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/21\">",
"      Dent J, Dodds WJ, Hogan WJ, Toouli J. Factors that influence induction of gastroesophageal reflux in normal human subjects. Dig Dis Sci 1988; 33:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/22\">",
"      Mittal RK, Rochester DF, McCallum RW. Sphincteric action of the diaphragm during a relaxed lower esophageal sphincter in humans. Am J Physiol 1989; 256:G139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/23\">",
"      Pandolfino JE, Kim H, Ghosh SK, et al. High-resolution manometry of the EGJ: an analysis of crural diaphragm function in GERD. Am J Gastroenterol 2007; 102:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/24\">",
"      Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992; 117:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/25\">",
"      Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/26\">",
"      Kahrilas PJ, Shi G, Manka M, Joehl RJ. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000; 118:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/27\">",
"      van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000; 119:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/28\">",
"      Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/29\">",
"      Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006; 130:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/30\">",
"      El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut 2007; 56:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/31\">",
"      de Vries DR, van Herwaarden MA, Smout AJ, Samsom M. Gastroesophageal pressure gradients in gastroesophageal reflux disease: relations with hiatal hernia, body mass index, and esophageal acid exposure. Am J Gastroenterol 2008; 103:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/32\">",
"      Corley DA, Kubo A, Zhao W. Abdominal obesity, ethnicity and gastro-oesophageal reflux symptoms. Gut 2007; 56:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/33\">",
"      Wu JC, Mui LM, Cheung CM, et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology 2007; 132:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/34\">",
"      Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/35\">",
"      Zheng Z, Margolis KL, Liu S, et al. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux. Gastroenterology 2008; 135:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/36\">",
"      Helm JF, Dodds WJ, Pelc LR, et al. Effect of esophageal emptying and saliva on clearance of acid from the esophagus. N Engl J Med 1984; 310:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/37\">",
"      Johnson LF. 24-hour pH monitoring in the study of gastroesophageal reflux. J Clin Gastroenterol 1980; 2:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/38\">",
"      Kahrilas PJ, Dodds WJ, Hogan WJ. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology 1988; 94:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/39\">",
"      Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987; 92:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/40\">",
"      Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991; 100:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/41\">",
"      Fletcher J, Wirz A, Young J, et al. Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/42\">",
"      Pandolfino JE, Zhang Q, Ghosh SK, et al. Acidity surrounding the squamocolumnar junction in GERD patients: \"acid pocket\" versus \"acid film\". Am J Gastroenterol 2007; 102:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/43\">",
"      Clarke AT, Wirz AA, Manning JJ, et al. Severe reflux disease is associated with an enlarged unbuffered proximal gastric acid pocket. Gut 2008; 57:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/44\">",
"      Korsten MA, Rosman AS, Fishbein S, et al. Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. Am J Med 1991; 90:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/45\">",
"      Sonnenberg A, Steinkamp U, Weise A, et al. Salivary secretion in reflux esophagitis. Gastroenterology 1982; 83:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/46\">",
"      Kahrilas PJ, Gupta RR. The effect of cigarette smoking on salivation and esophageal acid clearance. J Lab Clin Med 1989; 114:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/47\">",
"      Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991; 101:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/48\">",
"      Powell DW. Barrier function of epithelia. Am J Physiol 1981; 241:G275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/49\">",
"      Goldberg HI, Dodds WJ, Montgomery C, et al. Controlled production of acute esophagitis. Experimental animal model. Invest Radiol 1970; 5:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/50\">",
"      Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 1995; 108:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/51\">",
"      Orlando RC. Esophageal epithelial defenses against acid injury. Am J Gastroenterol 1994; 89:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/52\">",
"      Quigley EM, Turnberg LA. pH of the microclimate lining human gastric and duodenal mucosa in vivo. Studies in control subjects and in duodenal ulcer patients. Gastroenterology 1987; 92:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/53\">",
"      Meyers RL, Orlando RC. In vivo bicarbonate secretion by human esophagus. Gastroenterology 1992; 103:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/54\">",
"      Orlando RC, Lacy ER, Tobey NA, Cowart K. Barriers to paracellular permeability in rabbit esophageal epithelium. Gastroenterology 1992; 102:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/55\">",
"      Calabrese C, Fabbri A, Bortolotti M, et al. Dilated intercellular spaces as a marker of oesophageal damage: comparative results in gastro-oesophageal reflux disease with or without bile reflux. Aliment Pharmacol Ther 2003; 18:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/56\">",
"      Orlando RC, Bryson JC, Powell DW. Mechanisms of H+ injury in rabbit esophageal epithelium. Am J Physiol 1984; 246:G718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/57\">",
"      De Backer A, Haentjens P, Willems G. Hydrochloric acid. A trigger of cell proliferation in the esophagus of dogs. Dig Dis Sci 1985; 30:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/58\">",
"      Trimble KC, Douglas S, Pryde A, Heading RC. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995; 40:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13928/abstract/59\">",
"      Rodriguez-Stanley S, Robinson M, Earnest DL, et al. Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol 1999; 94:628.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2257 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13928=[""].join("\n");
var outline_f13_38_13928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H450877177\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISMS OF REFLUX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Transient lower esophageal sphincter relaxations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypotensive lower esophageal sphincter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hiatal hernia and the diaphragmatic sphincter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy and exogenous estrogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ESOPHAGEAL ACID CLEARANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Esophageal emptying in GERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Salivary function in GERD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MECHANISMS OF AND DEFENSES AGAINST ESOPHAGEAL INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Epithelial defense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Esophageal hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HELICOBACTER PYLORI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450877177\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2257|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/40/13952\" title=\"figure 1\">",
"      Esophageal acid clearance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15240?source=related_link\">",
"      Chest pain of esophageal origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/46/9959?source=related_link\">",
"      Helicobacter pylori and gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7527?source=related_link\">",
"      Hiatus hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/33/37393?source=related_link\">",
"      Patient information: Hiatal hernia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_38_13929="Pathogenesis of obesity";
var content_f13_38_13929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of obesity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13929/contributors\">",
"     George A Bray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13929/contributors\">",
"     F Xavier Pi-Sunyer, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13929/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/38/13929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity has many causes, each of which has a variable genetic component [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. At one extreme are the kinds of obesity caused by single-gene mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/4\">",
"     4",
"    </a>",
"    ]. At the other extreme are the kinds of obesity caused by various diseases (such as damage to the ventromedial hypothalamus) in subjects in whom obesity would otherwise not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the types of obesity caused by single gene defects, the genetic susceptibility to obesity, and the pathogenetic mechanisms that operate within this genetic framework to cause differences in total body fat content and in regional fat distribution.",
"   </p>",
"   <p>",
"    Other factors associated with the development of obesity, such as diet, lifestyle, drugs, and endocrine disorders, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link\">",
"     \"Etiology and natural history of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC MODELS OF OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five single-gene defects causing obesity in rodents have been identified (",
"    <a class=\"graphic graphic_table graphicRef76948 \" href=\"UTD.htm?35/36/36428\">",
"     table 1",
"    </a>",
"    ). Corresponding defects have been identified in several of these genes in humans (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Genetic factors in human obesity'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Agouti gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Agouti mouse model was important for the understanding of the role of the melanocortin peptides in obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/5\">",
"     5",
"    </a>",
"    ]. The agouti gene defect causes obesity and yellow coat color in mice. In these mice, the agouti-signaling protein, a 133 amino-acid peptide, is overexpressed in many tissues. This protein inhibits the binding of melanocyte-stimulating hormone (MSH) to its receptors in skin (melanocortin-1 receptor), thereby reducing melanin pigmentation. The agouti protein also competes with MSH for a melanocortin-4 receptor in the hypothalamus that modulates food intake [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/6\">",
"     6",
"    </a>",
"    ]. In the hypothalamus, MSH inhibits food intake, whereas agouti-related protein stimulates it.",
"   </p>",
"   <p>",
"    The effect of the agouti gene defect is mitigated by a mutation in another related gene, the mahogany gene. Mahogany is widely expressed in human tissues, including the hypothalamus. The mechanism by which the defective mahogany gene prevents diet-induced obesity in mice is unclear; it may facilitate the interaction of agouti with melanocortin receptors, or it may act in the hypothalamus to alter energy intake or expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Leptin gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ob or Lep gene codes for a protein called leptin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/8\">",
"     8",
"    </a>",
"    ]. Leptin-deficient mice (ob mice) have hyperphagia, insulin resistance, hyperinsulinemia, and infertility. Administration of leptin to these mice reverses all the features of this syndrome, indicating that it is the missing signal.",
"   </p>",
"   <p>",
"    Leptin is produced in fat cells, gut, and the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/9\">",
"     9",
"    </a>",
"    ]. It signals the brain about the quantity of stored fat. The correlation between serum leptin concentrations and body fat content in humans is approximately 0.8. This and other observations have led to the suggestion that, with increasing adiposity, leptin acts as a negative feedback \"adipostatic\" signal to brain centers to reduce energy intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obesity due to leptin deficiency has been found primarily in consanguineous families [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/2\">",
"     2",
"    </a>",
"    ]. However, most obese subjects do not have any abnormalities in the leptin gene, their serum leptin concentrations are high, and in preliminary studies administration of supraphysiological doses of leptin resulted in minimal weight loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link&amp;anchor=H12#H12\">",
"     \"Physiology of leptin\", section on 'Obesity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link&amp;anchor=H791048#H791048\">",
"     \"Physiology of leptin\", section on 'Leptin and disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aggregate of findings suggest that the primary role of leptin is to indicate whether somatic fat stores are sufficient for growth and reproduction. Inadequate stores would be signaled by a decline in serum leptin concentrations below a threshold which may be genetically or developmentally set; the result is hyperphagia, low energy output, and infertility. In contrast, a serum leptin concentration above this threshold may have little or no physiologic effect, resulting in neither hypophagia nor hypermetabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link\">",
"     \"Physiology of leptin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Leptin receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic",
"    <span class=\"nowrap\">",
"     (db/db)",
"    </span>",
"    mice and fatty (Zucker) rats have defects in the leptin receptor. Db mice are phenotypically identical to ob mice, indicating that obesity can be caused by a deficiency of leptin or by a genetic defect in the leptin receptor. Human obesity resulting from leptin receptor deficiency has been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link&amp;anchor=H11#H11\">",
"     \"Physiology of leptin\", section on 'Leptin receptor deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final two genes listed in the table are those for Fat and tubby (tub) mice, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fat mice lack carboxypeptidase E, an enzyme involved in the cleavage of many prohormones, including proinsulin. Obesity in one family was associated with mutations in the gene for prohormone convertase I, an enzyme with functions similar to carboxypeptidase E.",
"     </li>",
"     <li>",
"      Defects in the tub gene are associated with retinitis and other neurologic defects, including defects that result in hypothalamic damage and thereby stimulate appetite.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transgenic mice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of genetic factors in causing obesity can also be studied by manipulating the function of candidate genes for obesity in transgenic animals (",
"    <a class=\"graphic graphic_table graphicRef62642 \" href=\"UTD.htm?33/13/34011\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/10\">",
"     10",
"    </a>",
"    ]. The most striking changes in body weight are in transgenic mice in which the melanocortin-4 receptor has been deleted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/11\">",
"     11",
"    </a>",
"    ]. Mice lacking this receptor become hyperphagic and markedly obese. The melanocortin-3 receptor also appears to be important; per calorie consumed, mice lacking this receptor store more fat and have a lower lean body mass than normal mice [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/12\">",
"     12",
"    </a>",
"    ]. These observations suggest that functional receptors for MSH inhibit both food intake and the accumulation of body fat.",
"   </p>",
"   <p>",
"    Transgenic mice in which the serotonin-2C receptor has been eliminated have an increase in food intake, obesity, and seizures. This receptor is thought to mediate the action of serotonergic drugs to reduce food intake. The serotonin-1B receptor also may be important, because knock-out of this receptor blocks the anorectic effect of dexfenfluramine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link\">",
"     \"Drug therapy of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surprisingly, transgenic mice lacking neuropeptide Y receptor have normal amounts of fat even though neuropeptide Y is a potent stimulator of food intake [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secretion of gastric inhibitory polypeptide (GIP) occurs in response to fat or glucose absorption in the intestine. Wild type mice fed a high fat diet have an increase in GIP signaling, fat deposition, and insulin resistance, whereas mice lacking GIP receptors are protected from the obesity and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, GIP blockers may represent a potential treatment for obesity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS IN HUMAN OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of twins, adoptees, and families all suggest the existence of genetic factors in human obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The heritability of obesity estimated from twin studies is high, ranging between 0.6 and 0.9, with only slightly lower values in twins raised apart compared with those raised together. Similarly, in adoptees the body mass index correlates with that of their biologic parents rather than that of their adoptive parents.",
"   </p>",
"   <p>",
"    In addition to the heritability of weight, metabolic rate, thermic response to food, and spontaneous physical activity are to some extent heritable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/16\">",
"     16",
"    </a>",
"    ]. With respect to body weight, percentage of fat, fat mass, and estimated subcutaneous fat, there was approximately three times more variance among pairs than within pairs. Thus, both current weight status and the metabolic processes underlying weight gain have a strong inherited component.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a feature of at least 24 genetic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/10\">",
"     10",
"    </a>",
"    ]. The inheritance of nine of these disorders is autosomal dominant, 10 are autosomal recessive, and five are X-linked. The Bardet-Biedl and Prader-Willi syndromes are probably the best known examples of these traits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Prader-Willi syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Prader-Willi syndrome is a neurodegenerative disorder that is caused by genetic abnormalities of the long arm of chromosome 15 (q11-13). The majority of patients have a deletion of paternal DNA in this region; most of the remainder have two copies of maternal chromosome 15 (uniparental disomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The key genetic material usually lacking is the SNRPN gene, which codes for a small nuclear ribonucleoprotein thought to be involved in imprinting genes from both parents. The deletions can often be detected by fluorescence in situ hybridization; molecular analysis of the SNRPN gene can be done if a deletion is not detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16516?source=see_link\">",
"     \"Epidemiology and genetics of Prader-Willi syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link\">",
"     \"Basic principles of genetic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected infants have poor muscle tone and feed poorly at birth. Later their appetite becomes voracious and they become obese, have behavior problems (irritability, tantrums), delayed development, short stature, and, later, hypogonadotropic hypogonadism. Most boys have cryptorchidism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/19\">",
"     19",
"    </a>",
"    ]. Little information is available about adult patients with Prader-Willi (given their small numbers). However, in one report of 32 girls over age 15, primary amenorrhea was seen in 18 of 32 cases (56 percent), while 14 of 32 (44 percent) had spontaneous menarche (usually followed by irregular menses) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/19\">",
"     19",
"    </a>",
"    ]. This raises the question of the need for contraception in some adult patients with Prader-Willi syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Growth hormone secretion may be decreased and serum insulin-like growth factor 1 concentrations are low. There is no effective treatment for most of the problems, although administration of growth hormone accelerates growth and decreases body fat. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\", section on 'Growth hormone treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bardet-Biedl syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bardet-Biedl syndrome is an autosomal recessive disorder characterized by obesity and several other abnormalities, including microorchidism in men, intellectual disability (mental retardation), retinal dystrophy, polydactyly, renal malformations (particularly calyceal abnormalities), and polyuria and polydipsia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in at least 15 genes have been described in patients with this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/21\">",
"     21",
"    </a>",
"    ]. Disordered function of the cilia may be a fundamental defect in this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Common obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is a heritable trait, but the genes that contribute to the more common forms of obesity have been difficult to identify. However, genome wide association studies in large populations have identified polymorphisms in genes that are associated with obesity risk [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/23-29\">",
"     23-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variant in the FTO gene (fat mass and obesity associated) on chromosome 16 predisposes to type 2 diabetes through an effect on BMI [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/24\">",
"       24",
"      </a>",
"      ]. In addition, two studies suggest that this variant also affects the risk of obesity in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/24,30\">",
"       24,30",
"      </a>",
"      ]. In one, 16 percent of adults in 13 European cohorts were homozygous for the risk allele, and weighed on average 3 kg more than those without the risk allele [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/24\">",
"       24",
"      </a>",
"      ]. Both studies found an approximately 1.5-fold increase in the risk in obesity with the inherited risk genotype, which was seen in both children and adults. The authors of one report calculated that the FTO variant may account for approximately 22 percent of common obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a genome-wide association study of 16,000 individuals (and confirmed in additional populations), common variants near MC4R were associated with increasing body mass index in both children and adults [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/25\">",
"       25",
"      </a>",
"      ]. This suggests that there may be overlap in the genetic determinants of monogenic and multifactorial forms of obesity. Heterozygous mutations in the gene encoding the melanocortin-4 receptor (MC4R) are reported to be the most common monogenic cause of severe obesity in childhood in some [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/31-33\">",
"       31-33",
"      </a>",
"      ], but not all studies [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/34\">",
"       34",
"      </a>",
"      ]. Evidence from one patient with a homozygous mutation in the receptor suggests that MC4R mediates most of the anorectic effects of leptin in early childhood, but not the effect of leptin on linear growth and other endocrine axes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/33,35\">",
"       33,35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link\">",
"       \"Physiology of leptin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other genes may contribute to common forms of obesity including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutations in PCSK1 (prohormone convertase",
"      <span class=\"nowrap\">",
"       1/3)",
"      </span>",
"      gene are associated with monogenic obesity, but may also contribute to polygenic obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/27,36\">",
"       27,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain-derived neurotrophic factor (BDNF) may play a role in energy balance; BDNF haploinsufficiency is associated with childhood-onset obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In a whole-genome scan of four large populations, a common variant near the INSIG2 gene, which was present in approximately 10 percent of individuals, was associated with a higher risk of obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/39\">",
"       39",
"      </a>",
"      ]. However, this finding has not been replicated in all populations [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/40\">",
"       40",
"      </a>",
"      ]. This variant is likely to carry only a low relative risk in some populations, but the impact on health may be because of its prevalence.",
"     </li>",
"     <li>",
"      The gene for peroxisome-proliferator-activated receptor (PPAR) gamma 2, a transcription factor that has a key role in adipocyte differentiation. Mutations in this gene have been identified that accelerate the differentiation of adipocytes and are associated with obesity in some subjects; variants in this gene also may contribute to the observed variability in body mass index and insulin sensitivity in the general population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"       \"Thiazolidinediones in the treatment of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retinaldehyde is an intermediate metabolite between vitamin A and retinoic acid and can suppress adipogenesis in rodents. Using genetic engineering to increase retinaldehyde in adipose tissue protects against diet-induced obesity and insulin resistance in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/41\">",
"     41",
"    </a>",
"    ]. This effect is independent of retinoic acid, and is mediated at least in part, through inhibition of PPAR gamma activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BODY FAT DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with total body fat, the distribution of body fat between visceral and nonvisceral (subcutaneous) compartments and within different subcutaneous areas also has important genetic determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/42\">",
"     42",
"    </a>",
"    ]. Gonadal steroids play a major role in the distribution of body fat. At the onset of puberty, men become more muscular and have less fat, whereas women increase their body fat relative to their muscle mass. These differences persist throughout life and are reflected in the typical male and female fat distribution.",
"   </p>",
"   <p>",
"    With age, both gonadal steroid and growth hormone secretion decline, which may explain the rise in visceral fat with age in men. In women, higher serum testosterone concentrations are usually associated with increased visceral fat. Thus, the decline in growth hormone and the loss of estrogen at the time of the menopause may explain the relatively rapid increase in visceral fat in postmenopausal women.",
"   </p>",
"   <p>",
"    The distribution of body fat is important clinically. Visceral central adiposity is associated with a greater risk of metabolic and cardiovascular disorders including insulin resistance, type 2 diabetes mellitus, hypertension, and coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREDICTORS OF OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors associated with a high risk of obesity have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/43\">",
"     43",
"    </a>",
"    ]. Some are metabolic and others are socioeconomic. Among the former are a low metabolic rate, increased carbohydrate oxidation, insulin resistance, and low sympathetic activity. Among the latter are lower socioeconomic class, lower education level, and cessation of smoking.",
"   </p>",
"   <p>",
"    Weight gain is very common when people stop smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/44\">",
"     44",
"    </a>",
"    ]. This is thought to be mediated at least in part by nicotine withdrawal. The average weight gain is 4 to 5 kg in four to six months, but it can be much greater. It has been estimated that smoking cessation increases the odds of obesity compared with nonsmokers by 2.4 in men and 2.0 in women. These factors are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link\">",
"     \"Etiology and natural history of obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC BASIS FOR OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in body fat (both visceral and nonvisceral [subcutaneous]) requires that energy intake be increased over energy expenditure. However, the truth and simplicity of this statement of the first law of thermodynamics fail to include the modulating effect of other variables such as intrauterine growth, growth hormone and reproductive hormone secretion, and the feedback between energy intake and expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the feedback control system was illustrated in a careful study of 18 obese and 23 never-obese subjects who were monitored during caloric restriction and caloric excess [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/45\">",
"     45",
"    </a>",
"    ]. Weight loss of 10 to 20 percent was associated with a decrease in total and resting energy expenditure, a change that retarded further weight loss. Similarly, weight gain was associated with an increase in energy expenditure which retarded further weight gain. These observations suggest a mechanism that tends to maintain body weight, and lends support to the theory that behavior is not the sole determinant of obesity.",
"   </p>",
"   <p>",
"    One consequence of these changes in energy expenditure is that a formerly obese subject would require 15 percent fewer calories to maintain a \"normal\" body weight than someone with the same body composition who was never obese. The reductions in energy expenditure persist, even in adults who have maintained a reduced body weight for three to five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link&amp;anchor=H5#H5\">",
"     \"Dietary therapy for obesity\", section on 'Maintenance of weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Determinants of energy expenditure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low energy expenditure is one factor that can promote weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/46\">",
"     46",
"    </a>",
"    ]. Approximately 70 percent of energy expenditure is utilized for basal or resting metabolic processes. These include the energy involved in maintaining body temperature and ion gradients across cell membranes, cardiac and respiratory muscle function, gastrointestinal motility and secretion, and other metabolic storage and mobilization processes. Another 10 percent of energy expenditure is dissipated through the thermic responses to food. The final component of energy expenditure is activity and exercise.",
"   </p>",
"   <p>",
"    There is a strong relationship between total daily energy expenditure or resting energy expenditure and fat-free mass. Differences in fat-free mass account for approximately 80 percent of the variance in energy expenditure among subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Brown adipose tissue and body temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brown adipose tissue (BAT) regulates energy expenditure in small mammals and newborn infants. Through a process called adaptive thermogenesis, uncoupling protein 1 (UCP1), a marker gene for BAT, allows mitochondria to generate heat instead of ATP, thereby maintaining normal body temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BAT activity increases through childhood into adolescence, peaking approximately at 13 years of age in both boys and girls [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/48\">",
"     48",
"    </a>",
"    ]. Thereafter, the amount of BAT decreases with age, and BAT was previously thought not to play a role in adult thermogenesis. However, observational studies using PET-CT scanning have demonstrated the presence of metabolically active brown adipose tissue in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. Colder temperatures enhance 18F-fluorodeoxyglucose uptake by BAT, allowing visualization on PET-CT which was not seen in warm rooms.",
"   </p>",
"   <p>",
"    BAT is predominantly located in the supraclavicular and neck areas, and BAT activity is inversely related to BMI and percent body fat [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Thus, activation of BAT may be an important component of cold-stimulated energy expenditure in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Food",
"    </span>",
"    &nbsp;&mdash;&nbsp;The macronutrient composition of food affects energy expenditure, but not fat storage. In a randomized trial designed to determine whether the level of dietary protein affects body composition, weight gain, and energy expenditure, 28 individuals were randomly assigned to overfeeding with diets containing 5, 15, or 25 percent of energy from protein [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/53\">",
"     53",
"    </a>",
"    ]. Overconsumption of a diet with normal (15 percent of energy) or high (25 percent) compared with low (5 percent) protein increased resting energy expenditure and lean body mass. Although overall weight gain was less with a low protein diet (approximately 3 versus 6 kg), body fat accumulation was similar and was related to excess calories consumed rather than the protein composition of the diet.",
"   </p>",
"   <p>",
"    The thermal effect of food has an obligatory and a facultative component. A low thermic effect of food is associated with the development of obesity. This effect may be mediated by the sympathetic nervous system. Beta-adrenergic receptor knock-out mice develop severe obesity, due to a failure of diet-induced thermogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final component of energy expenditure is activity and exercise, known as activity thermogenesis, which includes both exercise and nonexercise activity thermogenesis (NEAT). An often overlooked component is spontaneous physical activity (fidgeting), which can account for the expenditure of 100 to 800",
"    <span class=\"nowrap\">",
"     kcal/day",
"    </span>",
"    and, along with genetic factors, is responsible for much of the variance in energy expenditure among individuals that is not explained by differences in fat-free mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=see_link\">",
"     \"Role of physical activity and exercise in obese adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A sedentary lifestyle is an important factor in the development of obesity, and for children this has been associated with many hours watching television, an effect that may persist into adulthood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=see_link&amp;anchor=H7#H7\">",
"     \"Definition; epidemiology; and etiology of obesity in children and adolescents\", section on 'Environmental factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and natural history of obesity\", section on 'Lifestyle'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     THE CONTROL SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feedback control system consists of the cellular processes for energy expenditure and for digestion, absorption, transport, and storage of nutrients and their subsequent mobilization and utilization as fuels. The central nervous system controller receives afferent signals from the periphery about deficits or surpluses of foods or alterations in the rate of fuel utilization. The controller processes this information and initiates metabolic and cognitive responses according to whether food is needed and if so, when and where to get it. The controller also initiates signals that alter metabolism of nutrients and the cognitive processes for food seeking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Afferent signals from fat and the gastrointestinal tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;The afferent signals that carry messages about surpluses or deficits of nutrients include neural circuits, circulating hormones, and nutrients themselves. Among them, leptin is one of the most potent. Leptin production is closely correlated with body fat mass, and leptin can reduce food intake and increase the activity of the sympathetic nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=see_link&amp;anchor=H2#H2\">",
"     \"Physiology of leptin\", section on 'Action of leptin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gastric distention and gastric contractions serve as signals for satiety and hunger, respectively. Nutrient absorption (or its lack) may also serve as signals leading to satiety (or hunger). As an example, a fall in blood glucose concentration of about 10 percent causes hunger in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/55\">",
"     55",
"    </a>",
"    ] and appears to be important in humans as well. Preventing the fall in blood glucose delays the onset of the next meal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ghrelin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several gut hormones may be involved in regulation of food intake. Cholecystokinin, enterostatin, and polypeptide Y 3-36 reduce food intake. Ghrelin, a 28 amino acid peptide produced in the stomach and duodenum, is an endogenous ligand for the growth hormone (GH) secretagogue receptor. This peptide has two major effects: it stimulates GH secretion and increases food intake in rodents and humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Serum concentrations increase in anticipation of a meal, and are suppressed by food ingestion. Ghrelin is not available for long-term studies in humans. However, in one study, GHRP-2, a synthetic analog of ghrelin, increased GH secretion and food intake in healthy men [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum ghrelin concentrations increase after diet-induced weight loss, suggesting it plays a role in the compensatory changes in appetite and energy expenditure that make maintenance of diet-induced weight loss difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/56\">",
"     56",
"    </a>",
"    ]. A similar increase in serum ghrelin occurs after exercise-induced weight loss (with no change in caloric intake) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/61\">",
"     61",
"    </a>",
"    ]. In contrast, in one study, gastric bypass was associated with low serum ghrelin concentrations, raising the possibility that its absence plays a role in the prolonged weight loss that often occurs after bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/56\">",
"     56",
"    </a>",
"    ]. However, not all studies have reported low serum ghrelin concentrations after gastric bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/62\">",
"     62",
"    </a>",
"    ], or after laparoscopic gastric banding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link\">",
"     \"Dietary therapy for obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ghrelin is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=see_link\">",
"     \"Ghrelin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Obestatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obestatin, a hormone that was isolated from rat stomach, is also encoded by the ghrelin gene, and opposes the effects of ghrelin on food intake. Treatment of rats with obestatin suppresses food intake, inhibits jejunal contraction, and decreases weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Central controller",
"    </span>",
"    &nbsp;&mdash;&nbsp;Messages from the periphery reach the brain via the circulation (leptin, glucose) or the autonomic nervous system (vagal afferents). Information from the gastrointestinal tract and oropharynx is neurally transmitted to the hindbrain and processed in the nucleus of the tractus solitarius. Leptin and possibly glucose and amino acids reach the brain by transport across the blood-brain barrier or directly in those regions of the brain in which this barrier is absent.",
"   </p>",
"   <p>",
"    Within the brain, several regions are important in processing information about food and relating it to body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/65\">",
"     65",
"    </a>",
"    ]. They are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nucleus of the tractus solitarius, the hindbrain area in which vagal and other neural inputs are integrated.",
"     </li>",
"     <li>",
"      The arcuate nucleus at the base of the hypothalamus integrates leptin signals by reciprocally changing the production and release of pairs of peptides (neuropeptide Y and agouti-related peptide) that increase food intake, and other pairs (cocaine-amphetamine-related transcript and proopiomelanocortin) that decrease food intake.",
"     </li>",
"     <li>",
"      The paraventricular nucleus (PVN) plays a central role in regulation of food intake. It receives a rich supply of signals from the peptides in the arcuate nucleus.",
"     </li>",
"     <li>",
"      The ventromedial hypothalamus, the destruction of which leads to increased food intake and profound obesity.",
"     </li>",
"     <li>",
"      The lateral hypothalamus which, if damaged, may decrease feeding and lower body weight.",
"     </li>",
"     <li>",
"      Selected regions of the amygdala, which may modulate feeding, either through connections to the ventromedial hypothalamus or elsewhere.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of monoamines, including norepinephrine and serotonin, and several neuropeptides are involved as neurotransmitters or neuromodulators of this control system. These transducers of afferent information modulate three processes: the search for and ingestion of food, the autonomic nervous system, and peripheral hormonal release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Stimulators of food intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, neuropeptide Y is one of the most potent stimulators of food intake known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33766?source=see_link\">",
"     \"Pancreatic polypeptide, peptide YY, and neuropeptide Y\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ghrelin, melanin-concentrating hormone, growth hormone-releasing hormone, norepinephrine, and orexin-A and orexin-B (also called hypocretin) also stimulate food intake. Two of these hormones, norepinephrine and neuropeptide Y, appear to stimulate predominantly carbohydrate intake [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of melanocyte-stimulating hormone has been demonstrated by the observations that disruption of the melanocortin-4 receptor in the hypothalamus leads to massive obesity, the identification of an agouti-related peptide which may compete with the hormone, and the description of obesity caused by proopiomelanocortin mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Inhibitors of food intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of hormones inhibit food intake. However, it is often difficult to separate effects on decreasing food intake from other effects such as aversion to food [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholecystokinin decreases food intake when administered either centrally or peripherally.",
"     </li>",
"     <li>",
"      Enterostatin is a penta peptide derived from a proenzyme in the gastrointestinal tract called procolipase. It reduces food intake, in particular fat intake, when given peripherally or into the brain.",
"     </li>",
"     <li>",
"      Infusion of the gut hormone peptide YY 3-36 suppresses food intake in both lean and obese subjects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=see_link&amp;anchor=H38#H38\">",
"       \"Drug therapy of obesity\", section on 'Peptides'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Efferent mediators",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sympathetic nervous system has a tonic role in maintaining energy expenditure and blood pressure. In addition, the activity of the peripheral sympathetic nerves supplying thermogenic tissues and food intake are inversely related. These nerves activate thermogenic tissues via beta-3-adrenergic receptors, resulting in a reduction in food intake. Animals lacking beta-3-receptors in adipose tissue do not reduce food intake in response to beta-3-agonist stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Glucocorticoids are a second key component of the efferent system, acting to increase food intake [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13929/abstract/66\">",
"       66",
"      </a>",
"      ]. In the absence of glucocorticoid, leptin deficiency or lesions of the ventromedial hypothalamus do not cause obesity. The permissive effect of glucocorticoids may be mediated via inhibition of sympathetic nervous system activity. Stimulation of food intake contributes to the weight gain in patients with Cushing's syndrome or those treated with exogenous glucocorticoids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     FOOD INTAKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modulation of food intake from meal to meal is normally integrated to maintain a constant weight status, and defective integration produces obesity or leanness. Food intake increases in early life to reach a peak in the second decade after which it declines. Men consistently eat more than women in concert with their higher fat-free mass. The age-related decline in caloric intake in men and women is associated with a slow decline in their energy expenditure. The fact that both men and women become more obese in middle age implies that the decline in energy expenditure is faster than the decline in food intake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=see_link&amp;anchor=H3#H3\">",
"     \"Dietary therapy for obesity\", section on 'Dietary energy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       \"Patient information: Weight loss treatments (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6744654\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Animal models of obesity have played an important role in understanding the molecular mechanisms of obesity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic models of obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic factors play a permissive role and interact with environmental factors to produce obesity. Studies suggest that heritable factors are responsible for 30 to 70 percent of the variation in adiposity. There are nearly 50 genes with polymorphisms related to obesity that have been identified by genome-wide scans. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic factors in human obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increase in body fat (both visceral and nonvisceral [subcutaneous]) requires that energy intake be increased over energy expenditure over an extended period of time. However, there is a feedback mechanism between energy intake and expenditure, a mechanism that tends to maintain body weight. Weight gain is associated with an increase in energy expenditure which retards further weight gain, whereas weight loss is associated with a decrease in total and resting energy expenditure, a change that retards further weight loss. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Physiologic basis for obesity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regulation of energy homeostasis and body weight is a complex process involving the central and sympathetic nervous systems, the melanocortin system, nutrient intake, gut hormones, the gut microbiome and adipose tissue itself. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'The control system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/1\">",
"      Berthoud HR, Morrison C. The brain, appetite, and obesity. Annu Rev Psychol 2008; 59:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/2\">",
"      Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101:4531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/3\">",
"      Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. J Clin Invest 2011; 121:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/4\">",
"      Bray, GA, Fisler, J, York, DA. Neuroendocrine control of the development of obesity: understanding gained from studies of experimental animal models. Front Neuroendocrinology 1990; 11:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/5\">",
"      Mountjoy KG. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochem J 2010; 428:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/6\">",
"      Shutter JR, Graham M, Kinsey AC, et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 1997; 11:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/7\">",
"      Gunn TM, Barsh GS. Mahogany/attractin: en route from phenotype to function. Trends Cardiovasc Med 2000; 10:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/8\">",
"      Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/9\">",
"      Dardeno TA, Chou SH, Moon HS, et al. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010; 31:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/10\">",
"      Rankinen T, P&eacute;russe L, Weisnagel SJ, et al. The human obesity gene map: the 2001 update. Obes Res 2002; 10:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/11\">",
"      Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/12\">",
"      Chen AS, Marsh DJ, Trumbauer ME, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/13\">",
"      Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/14\">",
"      Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/15\">",
"      Wardle J, Carnell S, Haworth CM, Plomin R. Evidence for a strong genetic influence on childhood adiposity despite the force of the obesogenic environment. Am J Clin Nutr 2008; 87:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/16\">",
"      P&eacute;russe L, Rankinen T, Zuberi A, et al. The human obesity gene map: the 2004 update. Obes Res 2005; 13:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/17\">",
"      Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009; 17:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/18\">",
"      Bonaglia MC, Ciccone R, Gimelli G, et al. Detailed phenotype-genotype study in five patients with chromosome 6q16 deletion: narrowing the critical region for Prader-Willi-like phenotype. Eur J Hum Genet 2008; 16:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/19\">",
"      Crin&ograve; A, Schiaffini R, Ciampalini P, et al. Hypogonadism and pubertal development in Prader-Willi syndrome. Eur J Pediatr 2003; 162:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/20\">",
"      Parfrey PS, Davidson WS, Green JS. Clinical and genetic epidemiology of inherited renal disease in Newfoundland. Kidney Int 2002; 61:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/21\">",
"      Janssen S, Ramaswami G, Davis EE, et al. Mutation analysis in Bardet-Biedl syndrome by DNA pooling and massively parallel resequencing in 105 individuals. Hum Genet 2011; 129:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/22\">",
"      Marion V, Stoetzel C, Schlicht D, et al. Transient ciliogenesis involving Bardet-Biedl syndrome proteins is a fundamental characteristic of adipogenic differentiation. Proc Natl Acad Sci U S A 2009; 106:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/23\">",
"      Willer CJ, Speliotes EK, Loos RJ, et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/24\">",
"      Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/25\">",
"      Loos RJ, Lindgren CM, Li S, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008; 40:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/26\">",
"      Thorleifsson G, Walters GB, Gudbjartsson DF, et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet 2009; 41:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/27\">",
"      Meyre D, Delplanque J, Ch&egrave;vre JC, et al. Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nat Genet 2009; 41:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/28\">",
"      Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/29\">",
"      Bradfield JP, Taal HR, Timpson NJ, et al. A genome-wide association meta-analysis identifies new childhood obesity loci. Nat Genet 2012; 44:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/30\">",
"      Dina C, Meyre D, Gallina S, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nat Genet 2007; 39:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/31\">",
"      Farooqi IS, Yeo GS, Keogh JM, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 2000; 106:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/32\">",
"      Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/33\">",
"      Lubrano-Berthelier C, Le Stunff C, Bougn&egrave;res P, Vaisse C. A homozygous null mutation delineates the role of the melanocortin-4 receptor in humans. J Clin Endocrinol Metab 2004; 89:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/34\">",
"      Jacobson P, Ukkola O, Rankinen T, et al. Melanocortin 4 receptor sequence variations are seldom a cause of human obesity: the Swedish Obese Subjects, the HERITAGE Family Study, and a Memphis cohort. J Clin Endocrinol Metab 2002; 87:4442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/35\">",
"      Savastano DM, Tanofsky-Kraff M, Han JC, et al. Energy intake and energy expenditure among children with polymorphisms of the melanocortin-3 receptor. Am J Clin Nutr 2009; 90:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/36\">",
"      Benzinou M, Creemers JW, Choquet H, et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat Genet 2008; 40:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/37\">",
"      Han JC, Liu QR, Jones M, et al. Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med 2008; 359:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/38\">",
"      El-Gharbawy AH, Adler-Wailes DC, Mirch MC, et al. Serum brain-derived neurotrophic factor concentrations in lean and overweight children and adolescents. J Clin Endocrinol Metab 2006; 91:3548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/39\">",
"      Herbert A, Gerry NP, McQueen MB, et al. A common genetic variant is associated with adult and childhood obesity. Science 2006; 312:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/40\">",
"      Lyon HN, Emilsson V, Hinney A, et al. The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts. PLoS Genet 2007; 3:e61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/41\">",
"      Ziouzenkova O, Orasanu G, Sharlach M, et al. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat Med 2007; 13:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/42\">",
"      Samaras K, Kelly PJ, Chiano MN, et al. Genetic and environmental influences on total-body and central abdominal fat: the effect of physical activity in female twins. Ann Intern Med 1999; 130:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/43\">",
"      Trasande L, Cronk C, Durkin M, et al. Environment and obesity in the National Children's Study. Environ Health Perspect 2009; 117:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/44\">",
"      Parsons AC, Shraim M, Inglis J, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2009; :CD006219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/45\">",
"      Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/46\">",
"      Heymsfield SB, Harp JB, Reitman ML, et al. Why do obese patients not lose more weight when treated with low-calorie diets? A mechanistic perspective. Am J Clin Nutr 2007; 85:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/47\">",
"      Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev 2004; 84:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/48\">",
"      Drubach LA, Palmer EL 3rd, Connolly LP, et al. Pediatric brown adipose tissue: detection, epidemiology, and differences from adults. J Pediatr 2011; 159:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/49\">",
"      van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med 2009; 360:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/50\">",
"      Cypess AM, Lehman S, Williams G, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med 2009; 360:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/51\">",
"      Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009; 360:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/52\">",
"      Ouellet V, Labb&eacute; SM, Blondin DP, et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J Clin Invest 2012; 122:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/53\">",
"      Bray GA, Smith SR, de Jonge L, et al. Effect of dietary protein content on weight gain, energy expenditure, and body composition during overeating: a randomized controlled trial. JAMA 2012; 307:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/54\">",
"      Bachman ES, Dhillon H, Zhang CY, et al. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002; 297:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/55\">",
"      Campfield LA, Brandon P, Smith FJ. On-line continuous measurement of blood glucose and meal pattern in free-feeding rats: the role of glucose in meal initiation. Brain Res Bull 1985; 14:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/56\">",
"      Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/57\">",
"      Tsch&ouml;p M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/58\">",
"      Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/59\">",
"      Druce MR, Wren AM, Park AJ, et al. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 2005; 29:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/60\">",
"      Laferr&egrave;re B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab 2005; 90:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/61\">",
"      Foster-Schubert KE, McTiernan A, Frayo RS, et al. Human plasma ghrelin levels increase during a one-year exercise program. J Clin Endocrinol Metab 2005; 90:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/62\">",
"      Holdstock C, Engstr&ouml;m BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88:3177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/63\">",
"      Hanusch-Enserer U, Cauza E, Brabant G, et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab 2004; 89:3352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/64\">",
"      Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/65\">",
"      Berthoud HR. Multiple neural systems controlling food intake and body weight. Neurosci Biobehav Rev 2002; 26:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/66\">",
"      Feillet CA. Food for thoughts: feeding time and hormonal secretion. J Neuroendocrinol 2010; 22:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13929/abstract/67\">",
"      Grujic D, Susulic VS, Harper ME, et al. Beta3-adrenergic receptors on white and brown adipocytes mediate beta3-selective agonist-induced effects on energy expenditure, insulin secretion, and food intake. A study using transgenic and gene knockout mice. J Biol Chem 1997; 272:17686.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5378 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13929=[""].join("\n");
var outline_f13_38_13929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6744654\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC MODELS OF OBESITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Agouti gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Leptin gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Leptin receptor gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transgenic mice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GENETIC FACTORS IN HUMAN OBESITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bardet-Biedl syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Common obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BODY FAT DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREDICTORS OF OBESITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PHYSIOLOGIC BASIS FOR OBESITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Determinants of energy expenditure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Brown adipose tissue and body temperature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Food",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      THE CONTROL SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Afferent signals from fat and the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Obestatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Central controller",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Stimulators of food intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Inhibitors of food intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Efferent mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      FOOD INTAKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6744654\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/5378\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/5378|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/36/36428\" title=\"table 1\">",
"      Single gene causes of obesity in animals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/13/34011\" title=\"table 2\">",
"      Transgenic obese mice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/5/32858?source=related_link\">",
"      Definition; epidemiology; and etiology of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8345?source=related_link\">",
"      Dietary therapy for obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33866?source=related_link\">",
"      Drug therapy of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16516?source=related_link\">",
"      Epidemiology and genetics of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3418?source=related_link\">",
"      Etiology and natural history of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16758?source=related_link\">",
"      Ghrelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33766?source=related_link\">",
"      Pancreatic polypeptide, peptide YY, and neuropeptide Y",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21144?source=related_link\">",
"      Role of physical activity and exercise in obese adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_38_13930="Overview of neutropenic fever syndromes";
var content_f13_38_13930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of neutropenic fever syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13930/contributors\">",
"     Eric Bow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13930/contributors\">",
"     John R Wingard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13930/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/38/13930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/38/13930/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/38/13930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H293581744\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients receiving cytotoxic antineoplastic therapy sufficient to adversely affect myelopoiesis and the developmental integrity of the gastrointestinal mucosa are at risk for invasive infection due to colonizing bacteria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungi that translocate across intestinal mucosal surfaces. Since the magnitude of the neutrophil-mediated component of the inflammatory response may be muted in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/1\">",
"     1",
"    </a>",
"    ], a fever may be the earliest and only sign of infection. It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly in order to avoid progression to a sepsis syndrome and possibly death.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the concepts related to neutropenic fever, including definitions of fever and neutropenia and categories of risk. The risk assessment and diagnostic approach to patients presenting with neutropenic fever are discussed in detail separately. The management of neutropenic fever syndromes in cancer patients at high and low risk for complications, and the prophylaxis of infections in such patients are also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9534148\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been developed for the evaluation and management of fever in neutropenic patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The recommendations below are generally in keeping with the 2010 Infectious Diseases Society of America (IDSA) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2\">",
"     2",
"    </a>",
"    ] and the 2013 American Society of Clinical Oncology (ASCO) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/4\">",
"     4",
"    </a>",
"    ]. These and other IDSA guidelines can be accessed through the IDSA&rsquo;s web site [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H293581920\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278237232\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of fever as an indicator of infection in neutropenic patients has varied. In 1868, Carl Wunderlich proposed that the mean normal body temperature was 37&deg;C (98.6&deg;F) with an upper limit of normal of 38&deg;C (100.4&deg;F), above which fever was defined [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Despite the observation that there is a range of normal body temperatures, in one survey, a majority (75 percent) of 270 medical professionals reported that normal body temperature is 37&deg;C (98.6&deg;F) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. A survey of members of the British Society for Haematology regarding their institutional definitions of fever identified 10 definitions of fever, ranging from a single temperature &gt;37.5&deg;C to either a single temperature &gt;39&deg;C or two successive temperatures &gt;38.4&deg;C [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/10\">",
"     10",
"    </a>",
"    ]. These beliefs notwithstanding, the empirically observed mean oral temperature of 148 healthy adults between ages 18 and 40 years was reported as 36.8&plusmn;0.4&deg;C (98.2&plusmn;0.7&deg;F) with a range of 35.6&deg;C (96.0&deg;F) to 38.2&deg;C (100.8&deg;F), the latter defining the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America defines fever in neutropenic patients as a single oral temperature of &gt;38.3&deg;C (101&deg;F) or a temperature of &gt;38.0&deg;C (100.4&deg;F) sustained for &gt;1 hour [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2\">",
"     2",
"    </a>",
"    ]. We agree with using this definition of fever in neutropenic patients. Similar definitions have been provided from South America, Europe, and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H981551211\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of neutropenia varies from institution to institution, but neutropenia is usually defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and severe neutropenia is usually defined as an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or an ANC that is expected to decrease to &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    over the next 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. The risk of clinically important infection rises as the neutrophil count falls below 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and is higher in those with a prolonged duration of neutropenia (&gt;7 days). For the purposes of this discussion,",
"    <strong>",
"     we will define neutropenia as an ANC &lt;500",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"    </strong>",
"    <br/>",
"    <br/>",
"    The ANC can be calculated by multiplying the total white blood cell (WBC) count by the percentage of polymorphonuclear cells (PMNs) and bands (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of neutropenia\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of the risk of neutropenia before the WBC and differential results are available is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154973874#H154973874\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Risk of neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H247552339\">",
"    <span class=\"h2\">",
"     Neutropenic fever syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of neutropenic fever syndromes have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The International Immunocompromised Host Society has classified initial neutropenic fever syndromes into the following three categories [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Microbiologically documented infection",
"      </strong>",
"      &ndash; Neutropenic fever with a clinical focus of infection and an associated pathogen.",
"     </li>",
"     <li>",
"      <strong>",
"       Clinically documented infection",
"      </strong>",
"      &ndash; Neutropenic fever with a clinical focus (eg, cellulitis, pneumonia), but without the isolation of an associated pathogen.",
"     </li>",
"     <li>",
"      <strong>",
"       Unexplained fever",
"      </strong>",
"      &ndash; Neutropenic fever with neither a clinical focus of infection nor an identified pathogen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     first neutropenic fever",
"    </strong>",
"    is the first febrile episode occurring during a given period of chemotherapy-induced neutropenia. A",
"    <strong>",
"     persistent neutropenic fever",
"    </strong>",
"    syndrome is a febrile episode without defervescence after at least five days of initial empiric broad-spectrum antibacterial therapy in high-risk neutropenic patients, or after at least two days in low-risk neutropenic patients. A",
"    <strong>",
"     recrudescent neutropenic fever syndrome",
"    </strong>",
"    is a febrile episode that recurs following initial defervescence during a course of broad-spectrum antibacterial therapy.",
"   </p>",
"   <p>",
"    The",
"    <strong>",
"     myeloid reconstitution syndrome",
"    </strong>",
"    is defined by fever and a new inflammatory focus or progression of a pre-existing inflammatory focus in temporal relationship to neutrophil recovery from aplasia. This syndrome is similar to the immune reconstitution inflammatory syndrome that can follow the initiation of antiretroviral therapy in patients with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477941076\">",
"    <span class=\"h1\">",
"     RISK OF SERIOUS COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation focuses on assessing the risk of serious complications. This risk assessment dictates the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Low-risk patients are defined as those who are expected to be neutropenic (absolute neutrophil count [ANC] &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &le;7 days and those with no comorbidities or evidence of significant hepatic or renal dysfunction.",
"      </strong>",
"      This group of patients has been well studied in randomized trials and has been shown to be at low risk for serious complications [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2\">",
"       2",
"      </a>",
"      ]. Most patients receiving chemotherapy for solid tumors are considered to be low-risk for complications requiring hospitalization or prolonging hospitalization.",
"     </li>",
"     <li>",
"      <strong>",
"       We define high-risk patients as those who are expected to be neutropenic (ANC &lt;500",
"       <span class=\"nowrap\">",
"        cells/microL)",
"       </span>",
"       for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high-risk, regardless of the duration of neutropenia.",
"      </strong>",
"      Other criteria that confer a high-risk status can be found in the Table (",
"      <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"       table 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Some experts have defined high-risk patients as those expected to have profound neutropenia (ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      for &gt;7 days based on experience that such patients are the most likely to have life-threatening complications [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. However, formal studies to clearly differentiate between patients with an ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are lacking. For the purposes of this discourse, we will combine these groups. Profound prolonged neutropenia (ie, ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      expected to last &gt;7 days) is most likely to occur in the pre-engraftment phase of hematopoietic cell transplantation (particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An alternative to using the clinical criteria described above is to use the Multinational Association for Supportive Care in Cancer (MASCC) risk index, which is a validated tool for measuring the risk for neutropenic fever-related medical complications (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/34/14881?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk assessment of patients with neutropenic fever is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372149507\">",
"    <span class=\"h1\">",
"     APPROACHES TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to the management of infection in patients at risk for neutropenic fever include primary prophylaxis, secondary prophylaxis, empiric therapy, and preemptive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372149515\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis involves the administration of an antimicrobial drug to prevent infection in patients at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link&amp;anchor=H1169494860#H1169494860\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372150101\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prophylaxis involves the administration of prophylactic doses of an antimicrobial drug to prevent recurrent infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link&amp;anchor=H564717720#H564717720\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\", section on 'Secondary prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372149523\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with chemotherapy-induced neutropenia, empiric therapy involves the initiation of therapy at the time of the onset of neutropenic fever, but before a firm diagnosis of infection has been established. Empiric antimicrobial therapy is a standard part of the management of neutropenic fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372149531\">",
"    <span class=\"h2\">",
"     Preemptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive therapy involves the initiation of therapy based upon screening with a sensitive microbiology assay (eg, antigen detection or molecular assays) in an attempt to detect the presence of a putative pathogen or early subclinical infection. Patients whose infections are detected using a preemptive approach are treated to avoid progression to invasive disease. A preemptive approach is sometimes used for antifungal therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H833586#H833586\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Preemptive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974423#H154974423\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Preemptive antifungal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86779646\">",
"    <span class=\"h1\">",
"     TEMPERATURE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated body temperature is the trigger for initiating an aggressive protocol of neutropenic fever management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the decision of whether to initiate the neutropenic fever management pathway may be based upon the difference of half a degree Celsius [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/18\">",
"     18",
"    </a>",
"    ], the reliability of the procedure used to obtain the temperature is extremely important. On the one hand, the risk of serious complications in high-risk patients who are not treated promptly is substantial. On the other hand, the potential toxicity of antimicrobial agents, the potential impact of antimicrobial use on resistance, and the costs of hospitalization and antimicrobial therapy are significant factors. It is therefore critical to accurately assess body temperature in order to aggressively treat patients with neutropenic fever and to avoid the overtreatment of stable neutropenic patients who do not have a fever.",
"   </p>",
"   <p>",
"    There is no universally preferred method for measuring body temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/19\">",
"     19",
"    </a>",
"    ], and the method used varies by institution. Most medical facilities use oral, infrared tympanic membrane, axillary, or rectal thermometry as a surrogate of core body temperature. We favor oral thermometry in patients without oral mucositis, and tympanic membrane thermometry or axillary thermometry in patients with oral mucositis. Each of these methods has shortcomings, and the use of each method requires that proper technique be used to obtain accurate results [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/8\">",
"     8",
"    </a>",
"    ]. The following issues apply to the use of the various thermometry techniques in neutropenic patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral thermometry is the most common method for measuring temperature. However, in neutropenic patients with oral mucositis, oral thermometry may be painful and may overestimate body temperature compared with tympanic membrane thermometry [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infrared tympanic membrane thermometry is non-invasive and convenient. However, falsely high readings may be obtained from the dependent ear [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/20,21\">",
"       20,21",
"      </a>",
"      ] and falsely low readings may occur if cerumen is present in the external auditory canal [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/8,22\">",
"       8,22",
"      </a>",
"      ]. Compared with direct measurement of core body temperature by pulmonary artery catheter readings, falsely low tympanic thermometry that might delay medical interventions have been observed in up to 21 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/20\">",
"       20",
"      </a>",
"      ]. Conversely, falsely high readings that might compel unnecessary interventions have been observed in up to 38 percent of patients whose temperatures were taken with a tympanic thermometer [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/20\">",
"       20",
"      </a>",
"      ]. Inconsistencies in operator technique and equipment maintenance also contribute to inaccuracies [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Like tympanic membrane thermometry, axillary thermometry may also result in falsely low or falsely high measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/20,26\">",
"       20,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rectal thermometry is",
"      <strong>",
"       not",
"      </strong>",
"      recommended in neutropenic or thrombocytopenic patients because it may increase risk for local mucosal trauma-induced bacteremia and bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis and treatment of fever are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8361?source=see_link\">",
"     \"Pathophysiology and treatment of fever in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533696\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contributory factors to the pathogenesis of neutropenic fever include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The direct effects of chemotherapy on mucosal barriers and the immune system.",
"     </li>",
"     <li>",
"      Breeches in host defenses related to the underlying malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chemotherapy-induced mucositis occurs throughout the alimentary system, and seeding of the bloodstream from endogenous flora in the gastrointestinal tract is believed to cause the majority of episodes of neutropenic fever (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=see_link\">",
"     \"Oral toxicity associated with chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=see_link\">",
"     \"Enterotoxicity of chemotherapeutic agents\"",
"    </a>",
"    ). Obstruction of lymphatics, the biliary tract,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bronchial, gastrointestinal, or urinary systems by tumor(s) or as a result of surgical procedures are also common causes of infection.",
"   </p>",
"   <p>",
"    Immune defects related to underlying hematologic disorders, in addition to the immunosuppressive effects of chemotherapy, also place patients at higher risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/27\">",
"     27",
"    </a>",
"    ]. In one study, patients who developed severe infection or died had a significant decrease in phagocytic activity of neutrophils compared with those with only a mild infection, suggesting that neutrophils might be preactivated and have reduced function prior to the initiation of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, the administration of chemotherapy not only decreases the number of neutrophils, but also results in chemotactic and phagocytic defects.",
"   </p>",
"   <p>",
"    The risk for specific types of infections is influenced by the nature of the underlying malignancy and its associated humoral or cellular immune deficits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal antibody production or clearing of immune complexes in multiple myeloma, chronic lymphocytic leukemia, and splenectomized (including functional asplenia) patients, results in an increased risk of sepsis from encapsulated organisms, including Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, as well as from Capnocytophaga canimorsus and Babesia spp. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and management of sepsis in the asplenic patient\", section on 'Bacterial pathogens'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features and management of sepsis in the asplenic patient\", section on 'Parasitic infections'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The T cell defects associated with lymphoma result in an increased risk of infection with intracellular pathogens, such as Listeria monocytogenes, Salmonella spp, Cryptococcus neoformans, and Mycobacterium tuberculosis. Patients with acute lymphocytic leukemia, central nervous system tumors, and other cancer patients receiving high-dose glucocorticoids are at increased risk for Pneumocystis jirovecii (formerly P. carinii) pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=see_link\">",
"       \"Epidemiology and pathogenesis of Listeria monocytogenes infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"       \"Microbiology and epidemiology of salmonellosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=see_link\">",
"       \"Microbiology and epidemiology of cryptococcal infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"       \"Epidemiology of tuberculosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533703\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infectious source is identified in approximately 20 to 30 percent of febrile neutropenic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2,29\">",
"     2,29",
"    </a>",
"    ]. Often the only evidence of infection is bacteremia, which is documented in 10 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately 80 percent of identified infections are believed to arise from the patient's endogenous flora [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/30\">",
"     30",
"    </a>",
"    ]. The Table lists the range of pathogens found in patients with chemotherapy-induced neutropenia (",
"    <a class=\"graphic graphic_table graphicRef63465 \" href=\"UTD.htm?0/44/718\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533710\">",
"    <span class=\"h2\">",
"     Bacterial pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative bacilli, particularly Pseudomonas aeruginosa, were the most commonly identified pathogens in neutropenic patients until the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequently, gram-positive bacteria have become the most common pathogens. In a survey of 49 hospitals in the United States in 1995 and 2000, gram-positive organisms accounted for 62 and 76 percent of all bloodstream infections, respectively, whereas gram-negative organisms accounted for only 22 and 14 percent of all bloodstream infections, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/32\">",
"     32",
"    </a>",
"    ]. Common gram-positive cocci include Staphylococcus epidermidis (by far the most common), Staphylococcus aureus, and streptococci; less common gram-positive organisms include Corynebacterium jeikeium, Bacillus spp, Leuconostoc spp,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    spp, Propionibacterium acnes, and Rhodococcus spp [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of changes in practice likely account for the trend toward gram-positive infections, including the introduction of long-term indwelling central venous catheters, the use of empiric antibiotic regimens for neutropenic fever designed to cover P. aeruginosa, the use of prophylactic antimicrobials that are primarily active against gram-negative pathogens (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ), and newer chemotherapeutic regimens.",
"   </p>",
"   <p>",
"    The following observations have been made about bacterial infections in neutropenic patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteria are the most frequent infectious causes of neutropenic fever [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gram-negative bacteria (eg, P. aeruginosa) are generally associated with the most serious infections.",
"     </li>",
"     <li>",
"      There has been a shift from gram-negative bacteria to gram-positive bacteria in documented infections.",
"     </li>",
"     <li>",
"      S. epidermidis is the most common gram-positive pathogen, accounting for approximately one-half of all infections due to gram-positive infections. It is much less virulent than other bacterial pathogens.",
"     </li>",
"     <li>",
"      Among gram-positive bacteria, S. aureus and some viridians streptococci can cause serious infections.",
"     </li>",
"     <li>",
"      Although anaerobic bacteria are abundant in the alimentary tract, they are infrequent pathogens in patients with neutropenic fever. However, they can contribute to the pathogenesis of necrotizing mucositis, sinusitis, periodontal cellulitis, perirectal cellulitis, intraabdominal or pelvic infection, neutropenic enterocolitis (typhlitis), and anaerobic bacteremia.",
"     </li>",
"     <li>",
"      Polymicrobial infections are infrequent, but their frequency appears to be rising [",
"      <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533717\">",
"    <span class=\"h2\">",
"     Fungal pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal pathogens are common in high-risk patients with neutropenic fever (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ), but are uncommon in low-risk patients. The risk for invasive fungal infections increases with the duration and severity of neutropenia, prolonged antibiotic use, and number of chemotherapy cycles. Fungi are rarely the cause of the first febrile episode in neutropenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/35\">",
"     35",
"    </a>",
"    ]. More commonly, invasive fungal infections occur later as a cause of persistent or recurrent neutropenic fever. However, fungal infections can occasionally present early or even prior to initial chemotherapy.",
"   </p>",
"   <p>",
"    In an autopsy study of patients who died after prolonged febrile neutropenia between 1966 and 1975, 69 percent of patients had evidence of invasive fungal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/36\">",
"     36",
"    </a>",
"    ]. It is important to note that this study was done before either antifungal prophylaxis or early diagnosis and treatment of invasive fungal infections was routine. Also, diagnostic methods have improved over time.",
"    <br/>",
"   </p>",
"   <p>",
"    The following observations have been made about fungal infections in general and about specific fungal pathogens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fungi are rarely identified as the cause of initial fever during neutropenia. More commonly, they are identified as causes of persistent or recurrent fever beyond the first week of neutropenia.",
"     </li>",
"     <li>",
"      Candida spp and Aspergillus spp account for most invasive fungal infections during neutropenia. The former are acquired through gastrointestinal tract colonization and translocation across damaged intestinal epithelial surface. The latter are acquired by inhalation of airborne spores (conidia) into the upper and lower respiratory tract followed by germination and invasive hyphal growth.",
"     </li>",
"     <li>",
"      Fever is often the sole manifestation of candidemia. Erythematous macronodular skin nodules occur in some patients with candidemia. Among patients who develop disseminated candidiasis following chemotherapy, hepatosplenic involvement is common; signs and symptoms are often not present until the neutropenia resolves. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link\">",
"       \"Epidemiology and pathogenesis of candidemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=see_link\">",
"       \"Hepatosplenic candidiasis (chronic disseminated candidiasis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Candida albicans accounts for the majority of candidemias; C. glabrata, C. tropicalis, and other Candida spp account for the remainder. A higher proportion of candidemias are due to non-albicans Candida species when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      prophylaxis has been administered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link&amp;anchor=H3#H3\">",
"       \"Epidemiology and pathogenesis of candidemia in adults\", section on 'Prevalence of Candida species'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Candida spp are common fungal causes of central venous catheter-associated infections and can cause disseminated candidiasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H28#H28\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Catheter removal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aspergillus spp is a common fungal pathogen in immunocompromised hosts, which may occur following the inhalation of infective conidia (spores); manifestations primarily affect the lower respiratory tract (pneumonia) and upper respiratory tract (sinusitis), but may also involve the central nervous system, bones, and skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The agents of mucormycosis can cause life-threatening rhino-orbital-cerebral, pulmonary,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      disseminated infections in immunocompromised hosts. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fusarium spp have been increasingly reported to cause invasive fungal infections in the immunocompromised host. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link&amp;anchor=H473991967#H473991967\">",
"       \"Mycology, pathogenesis, and epidemiology of Fusarium infection\", section on 'Immunocompromised patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reactivation of endemic fungi (Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides spp) should also be considered in patients who have lived in or traveled to endemic areas, particularly in the setting of prolonged glucocorticoid use or other immunosuppression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathogenesis and clinical features of pulmonary histoplasmosis\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\", section on 'Risk factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=see_link&amp;anchor=H6#H6\">",
"       \"Mycology, pathogenesis, and epidemiology of blastomycosis\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H2#H2\">",
"       \"Primary coccidioidal infection\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prophylaxis and empiric therapy of invasive fungal infections in high-risk patients (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ) are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154974350#H154974350\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Addition of an antifungal agent'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533724\">",
"    <span class=\"h2\">",
"     Viral pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral infections, especially human herpesviruses, are common in high-risk patients with chemotherapy-induced neutropenia (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ), and are effectively prevented with antiviral prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most herpes simplex virus (HSV)-1 and -2 infections in adults are due to reactivation of latent infections in seropositive patients. The likelihood of reactivation is influenced by the intensity of the chemotherapy regimen. Reactivation occurs in two-thirds of seropositive patients undergoing induction chemotherapy for acute myelogenous leukemia and those undergoing hematopoietic cell transplantation (HCT) in the absence of antiviral prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Ulcerations of the oral or esophageal mucosa, and ulcers or vesicles of lips, genitalia, skin, or perianal areas are the most common manifestations. HSV can cause a wide variety of syndromes, including encephalitis, meningitis, myelitis, esophagitis, pneumonia, hepatitis, erythema multiforme, and ocular disease.",
"   </p>",
"   <p>",
"    Herpes zoster, which is caused by varicella-zoster virus, often presents in an atypical disseminated pattern involving multiple dermatomes or widespread skin dissemination in immunocompromised hosts. Immunocompromised patients with disseminated varicella-zoster virus (VZV) infection can have pulmonary involvement and should be placed on respiratory precautions to prevent aerosolized transmission to susceptible individuals.",
"   </p>",
"   <p>",
"    Reactivation or, less commonly, primary acquisition of other human herpesviruses (cytomegalovirus, Epstein-Barr virus, human herpesvirus 6) can also occur in this patient population as a result of immunosuppression or receipt of blood products or stem cells, respectively. Allogeneic HCT recipients are at particularly high risk for these infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infections caused by respiratory viruses have been documented with increasing frequency and occur commonly in neutropenic patients; these include influenza virus, respiratory syncytial virus, parainfluenza virus, adenovirus, and metapneumovirus. The risk for infection by these organisms tends to coincide with respiratory virus outbreaks in the general population. Severity of infection and, specifically, the rate of progression from upper respiratory tract disease to lower respiratory tract disease, is dependent on degree, duration, and type of immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link\">",
"     \"Epidemiology of influenza\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=see_link\">",
"     \"Parainfluenza viruses in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=see_link\">",
"     \"Human metapneumovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9533731\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of tuberculosis should be considered in patients with epidemiologic risk factors, especially in those with prolonged glucocorticoid use or other forms of immunosuppression that increase the risk (eg, a tumor necrosis factor-alpha inhibitor). Babesia microti or B. divergens infection can cause overwhelming sepsis in patients with compromised splenic function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=see_link\">",
"     \"Epidemiology and pathogenesis of babesiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9534256\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly in order to avoid progression to a sepsis syndrome and possibly death. In all cancer patients presenting with neutropenic fever, empiric antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105837715\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reliable method for obtaining body temperature must be used and a mechanism for estimating the absolute neutrophil count (ANC) is mandatory (see",
"    <a class=\"local\" href=\"#H86779646\">",
"     'Temperature measurement'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H981551211\">",
"     'Neutropenia'",
"    </a>",
"    above). The risk of neutropenia, the risk of complications from neutropenic fever, and the risk of sepsis must be assessed quickly. These issues are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154973860#H154973860\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Initial assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link&amp;anchor=H453916929#H453916929\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\", section on 'Initial assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients and their families should be instructed by their oncologist to inform healthcare providers in the triage setting about recent chemotherapy, and providers in the triage setting should ask cancer patients who do not offer this information about recent chemotherapy. Receipt of systemic antineoplastic therapy within the preceding six weeks has been advocated for use in emergency triage departments to identify patients who are likely to be neutropenic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24660640\">",
"    <span class=\"h2\">",
"     Timing of antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Oncology and the Northern Ireland Cancer Network recommend that empiric broad-spectrum antibacterial therapy be initiated immediately after blood cultures have been obtained and before any other investigations have been completed in all patients with neutropenic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/12,39\">",
"     12,39",
"    </a>",
"    ]. International guidelines advocate the administration of empiric antibacterial therapy within",
"    <strong>",
"     60 minutes",
"    </strong>",
"    of presentation in all patients presenting with a neutropenic fever (",
"    <a class=\"graphic graphic_algorithm graphicRef57616 \" href=\"UTD.htm?35/16/36100\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/4,39-41\">",
"     4,39-41",
"    </a>",
"    ]. We agree with both of these recommendations.",
"   </p>",
"   <p>",
"    The optimal timing for the administration of the first dose of empiric antibacterial therapy in patients with neutropenic fever in order to prevent harm is not known. Early studies of patients with neutropenic fever documented mortality rates of up to a 70 percent if initiation of antibiotics was delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/42\">",
"     42",
"    </a>",
"    ]. In a retrospective cohort study of 2731 patients with septic shock (only 7 percent of whom were neutropenic), each hour delay in initiating effective antimicrobials decreased survival by approximately 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/43\">",
"     43",
"    </a>",
"    ]. The in-hospital mortality among adult patients with severe sepsis or septic shock decreased from 33 to 20 percent (odds ratio 0.30, 95% CI 0.11-0.83) when the time from triage to appropriate antimicrobial therapy was one hour or less compared with more than one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The successful management of neutropenic fever and sepsis syndromes is a time-dependent process analogous to acute stroke or ST-segment elevation myocardial infarction syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/39\">",
"     39",
"    </a>",
"    ]. In one study, almost one-half (45 percent) of febrile neutropenic cancer patients presenting to emergency rooms in France had evidence of a sepsis syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/45\">",
"     45",
"    </a>",
"    ]. Approximately 2 to 5 percent of febrile neutropenic patients seeking medical care from the emergency department require critical care services [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported median times from assessment of febrile neutropenic cancer patients in an emergency department setting to the initiation of empiric antibacterial therapy have ranged widely from 15 minutes to over 9 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/10,46,49-52\">",
"     10,46,49-52",
"    </a>",
"    ]. Audits from the United Kingdom reported that only 18 to 26 percent of patients received initial empiric antibacterial therapy within the one hour &ldquo;door-to-needle&rdquo; target time frame [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/10,52\">",
"     10,52",
"    </a>",
"    ]. The most common reasons for failure to comply with this time frame have included failure to administer the initial dose of the empiric antibacterial regimen until the patient has been transferred from the emergency department to the inpatient ward, prolonged time between arrival and clinical assessment, lack of awareness of the natural history of neutropenic fever syndromes and their evolution to severe sepsis or shock, failure of the emergency department to stock the appropriate antibacterial therapy, and neutropenic fever protocols not being readily available in the emergency department for quick reference [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24660668\">",
"    <span class=\"h2\">",
"     Non-specific presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The febrile neutropenic patient who is developing a neutropenic",
"    <span class=\"nowrap\">",
"     fever/sepsis",
"    </span>",
"    syndrome may seek medical attention with non-specific symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/53\">",
"     53",
"    </a>",
"    ], and may manifest muted signs of an inflammatory process [",
"    <a class=\"abstract\" href=\"UTD.htm?13/38/13930/abstract/1\">",
"     1",
"    </a>",
"    ]. In order to establish a diagnosis of neutropenic fever, the likelihood of the states of neutropenic fever must be ascertained. Laboratory confirmation of neutropenia may not be achievable in the recommended time frame of one hour. Accordingly, the index of suspicion based upon limited patient history with or without vital signs must be raised very early in the triage process by taking a medical history. The risk of neutropenia, along with information obtained from basic vital signs, can be used to develop a management plan and administer initial empiric antibacterial therapy even before the results of basic laboratory investigations are available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154973874#H154973874\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Risk of neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105840692\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once empiric antibacterial therapy has been started, all patients should have a careful history and detailed physical examination, as well as laboratory, microbiology, and imaging studies (",
"    <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"     table 3",
"    </a>",
"    ). This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H805986666\">",
"    <span class=\"h2\">",
"     Treatment regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific treatment regimens for patients presenting with neutropenic fever who are high-risk or low-risk for serious complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/31/36338?source=see_link\">",
"       \"Patient information: When to worry about a fever (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278237216\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer patients receiving cytotoxic antineoplastic therapy sufficient to adversely affect myelopoiesis and the integrity of the gastrointestinal mucosa are at risk for invasive infection due to colonizing bacteria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fungi that translocate across intestinal mucosal surfaces. Since the magnitude of the neutrophil-mediated component of the inflammatory response may be muted in neutropenic patients, a fever may be the earliest and only sign of infection. It is critical to recognize neutropenic fever early and to initiate empiric systemic antibacterial therapy promptly in order to avoid progression to a sepsis syndrome and possibly death. (See",
"      <a class=\"local\" href=\"#H293581744\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fever in neutropenic patients is defined as a single oral temperature of &gt;38.3&deg;C (101&deg;F) or a temperature of &gt;38.0&deg;C (100.4&deg;F) sustained for &gt;1 hour. (See",
"      <a class=\"local\" href=\"#H278237232\">",
"       'Fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe neutropenia is usually defined as an absolute neutrophil count (ANC) &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      or an ANC that is expected to decrease to &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      over the next 48 hours (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). The risk of clinically important infection rises as the neutrophil count falls below 500",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H981551211\">",
"       'Neutropenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is crucial to assess the risk for serious complications in patients with neutropenic fever, since this assessment will dictate the approach to therapy, including the need for inpatient admission, IV antibiotics, and prolonged hospitalization. (See",
"      <a class=\"local\" href=\"#H477941076\">",
"       'Risk of serious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low-risk patients with neutropenic fever are those in whom the duration of neutropenia (ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      is expected to be &le;7 days, and those with no comorbidities or evidence of significant hepatic or renal dysfunction. Most patients receiving chemotherapy for solid tumors or lymphoma are considered to be low-risk. (See",
"      <a class=\"local\" href=\"#H477941076\">",
"       'Risk of serious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We define high-risk patients with neutropenic fever as those who are expected to be neutropenic (ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high-risk, regardless of the duration of neutropenia. Other criteria that confer a high-risk status can be found in the Table (",
"      <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"       table 1",
"      </a>",
"      ). Profound prolonged neutropenia (ie, ANC &le;100",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      expected to last &gt;7 days) is most likely to occur in the preengraftment phase of hematopoietic cell transplantation (HCT, particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia. (See",
"      <a class=\"local\" href=\"#H477941076\">",
"       'Risk of serious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An infectious source is identified in approximately 20 to 30 percent of febrile neutropenic episodes. Often the only evidence of infection is bacteremia, which is documented in 10 to 25 percent of patients. Approximately 80 percent of identified infections are believed to arise from the patient's endogenous flora. Gram-positive bacteria are the most common causes of infection in neutropenic patients, but gram-negative bacteria (eg, P. aeruginosa) are generally associated with the most serious infections. The Table lists the range of pathogens found in patients with chemotherapy-induced neutropenia (",
"      <a class=\"graphic graphic_table graphicRef63465 \" href=\"UTD.htm?0/44/718\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9533703\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fungal pathogens are more common in high-risk patients with prolonged persistent or recrudescent neutropenic fever syndromes, but are uncommon in low-risk patients. Candida and Aspergillus spp account for most invasive fungal infections during neutropenia. (See",
"      <a class=\"local\" href=\"#H9533717\">",
"       'Fungal pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A reliable method for obtaining body temperature must be used and a mechanism for estimating the ANC is mandatory (see",
"      <a class=\"local\" href=\"#H86779646\">",
"       'Temperature measurement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H981551211\">",
"       'Neutropenia'",
"      </a>",
"      above). The risk of neutropenia, the risk of complications from neutropenic fever, and the risk of sepsis must be assessed quickly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link&amp;anchor=H154973860#H154973860\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\", section on 'Initial assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients and their families should be instructed by their oncologist to inform healthcare providers in the triage setting about recent chemotherapy, and providers in the triage setting should ask cancer patients who do not offer this information about recent chemotherapy. Receipt of systemic antineoplastic therapy within the preceding six weeks has been advocated for use in emergency triage departments to identify patients who are likely to be neutropenic. (See",
"      <a class=\"local\" href=\"#H105837715\">",
"       'Initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients presenting with neutropenic fever, empiric initial broad-spectrum antibacterial therapy should be initiated immediately after blood cultures have been obtained and before any other investigations have been completed. Empiric antibacterial therapy should be started within 60 minutes of presentation in all patients presenting with neutropenic fever (",
"      <a class=\"graphic graphic_algorithm graphicRef57616 \" href=\"UTD.htm?35/16/36100\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24660640\">",
"       'Timing of antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once empiric antibacterial therapy has been started, all patients should have a careful history and detailed physical examination, as well as laboratory, microbiology, and imaging studies (",
"      <a class=\"graphic graphic_table graphicRef50509 \" href=\"UTD.htm?23/55/24444\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"       \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Specific treatment regimens for high-risk and low-risk patients presenting with neutropenic fever are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/1\">",
"      Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/2\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/4\">",
"      Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31:794.",
"     </a>",
"    </li>",
"    <li>",
"     Standards, practice guidelines, and statements developed and/or endorsed by IDSA. file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     Wunderlich CA, Seguin E. Medical thermometry and human temperature, William Wood &amp; Co, New York 1871.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/7\">",
"      Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 1992; 268:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/8\">",
"      Davie A, Amoore J. Best practice in the measurement of body temperature. Nurs Stand 2010; 24:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/9\">",
"      Mackowiak PA, Wasserman SS. Physicians' perceptions regarding body temperature in health and disease. South Med J 1995; 88:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/10\">",
"      Clarke RT, Warnick J, Stretton K, Littlewood TJ. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. Br J Haematol 2011; 153:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/11\">",
"      Santolaya ME, Rabagliati R, Bidart T, et al. [Consensus: Rational approach towards the patient with cancer, fever and neutropenia]. Rev Chilena Infectol 2005; 22 Suppl 2:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/12\">",
"      Link H, B&ouml;hme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 Suppl 2:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/13\">",
"      Jun HX, Zhixiang S, Chun W, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 2005; 26 Suppl 2:S128.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on February 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/15\">",
"      From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990; 161:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/16\">",
"      Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol 2009; 46:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/17\">",
"      Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/18\">",
"      Dzarr AA, Kamal M, Baba AA. A comparison between infrared tympanic thermometry, oral and axilla with rectal thermometry in neutropenic adults. Eur J Oncol Nurs 2009; 13:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/19\">",
"      Ciuraru NB, Braunstein R, Sulkes A, Stemmer SM. The influence of mucositis on oral thermometry: when fever may not reflect infection. Clin Infect Dis 2008; 46:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/20\">",
"      Farnell S, Maxwell L, Tan S, et al. Temperature measurement: comparison of non-invasive methods used in adult critical care. J Clin Nurs 2005; 14:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/21\">",
"      Fulbrook P. Core body temperature measurement: a comparison of axilla, tympanic membrane and pulmonary artery blood temperature. Intensive Crit Care Nurs 1997; 13:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/22\">",
"      Doezema D, Lunt M, Tandberg D. Cerumen occlusion lowers infrared tympanic membrane temperature measurement. Acad Emerg Med 1995; 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/23\">",
"      O'Toole S. Alternatives to mercury thermometers. Prof Nurse 1997; 12:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/24\">",
"      Fisk J, Arcona S. Tympanic membrane vs. pulmonary artery thermometry. Nurs Manage 2001; 32:42, 45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/25\">",
"      Jevon P, Jevon M. Using a tympanic thermometer. Nurs Times 2001; 97:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/26\">",
"      Erickson RS, Meyer LT, Woo TM. Accuracy of chemical dot thermometers in critically ill adults and young children. Image J Nurs Sch 1996; 28:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/27\">",
"      Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis 2011; 53:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/28\">",
"      H&uuml;bel K, Hegener K, Schnell R, et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 1999; 78:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/29\">",
"      Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/30\">",
"      Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/31\">",
"      Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/32\">",
"      Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/33\">",
"      Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005; 103:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/34\">",
"      Pagano L, Caira M, Nosari A, et al. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the Hema e-Chart Registry. Arch Intern Med 2011; 171:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/35\">",
"      Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 2008; 26:5684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/36\">",
"      Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy study. Am J Clin Pathol 1979; 72:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/37\">",
"      Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983; 99:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/38\">",
"      Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305:63.",
"     </a>",
"    </li>",
"    <li>",
"     Bell MS, Scullen P, McParlan D, et al. Neutropenic sepsis guidelines. Northern Ireland Cancer Network, Belfast 2010. p. 1-11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/40\">",
"      Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.",
"     </a>",
"    </li>",
"    <li>",
"     Chemotherapy services in England: Ensuring quality and safety. National Chemotherapy Advisory Group, London 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/42\">",
"      Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/43\">",
"      Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/44\">",
"      Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/45\">",
"      Andr&eacute; S, Taboulet P, Elie C, et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care 2010; 14:R68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/46\">",
"      Courtney DM, Aldeen AZ, Gorman SM, et al. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist 2007; 12:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/47\">",
"      Schimpff SC, Gaya H, Klastersky J, et al. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. J Infect Dis 1978; 137:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/48\">",
"      Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/49\">",
"      Nirenberg A, Mulhearn L, Lin S, Larson E. Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Oncol Nurs Forum 2004; 31:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/50\">",
"      Richardson S, Pallot D, Hughes T, Littlewood T. Improving management of neutropenic sepsis in the emergency department. Br J Haematol 2009; 144:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/51\">",
"      Amado VM, Vilela GP, Queiroz A Jr, Amaral AC. Effect of a quality improvement intervention to decrease delays in antibiotic delivery in pediatric febrile neutropenia: a pilot study. J Crit Care 2011; 26:103.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/52\">",
"      Okera M, Chan S, Dernede U, et al. A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings. Br J Cancer 2011; 104:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/38/13930/abstract/53\">",
"      McKenzie H, Hayes L, White K, et al. Chemotherapy outpatients' unplanned presentations to hospital: a retrospective study. Support Care Cancer 2011; 19:963.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16708 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13930=[""].join("\n");
var outline_f13_38_13930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H278237216\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293581744\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9534148\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H293581920\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278237232\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H981551211\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H247552339\">",
"      Neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477941076\">",
"      RISK OF SERIOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H372149507\">",
"      APPROACHES TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372149515\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372150101\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372149523\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372149531\">",
"      Preemptive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86779646\">",
"      TEMPERATURE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9533696\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9533703\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9533710\">",
"      Bacterial pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9533717\">",
"      Fungal pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9533724\">",
"      Viral pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9533731\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9534256\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105837715\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24660640\">",
"      Timing of antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24660668\">",
"      Non-specific presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105840692\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H805986666\">",
"      Treatment regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H278237216\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16708\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16708|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/16/36100\" title=\"algorithm 1\">",
"      Neutropenic fever sepsis algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16708|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/26/40364\" title=\"table 1\">",
"      High-risk patients with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/44/718\" title=\"table 2\">",
"      Pathogens in neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/55/24444\" title=\"table 3\">",
"      Diagnostic evaluation fever and neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/34/14881?source=related_link\" title=\"calculator 2\">",
"      Calculator: Multinational Association for Supportive Care in Cancer (MASCC) risk index for patients with neutropenic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9993?source=related_link\">",
"      Epidemiology and pathogenesis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/16/42248?source=related_link\">",
"      Epidemiology and pathogenesis of babesiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10071?source=related_link\">",
"      Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37254?source=related_link\">",
"      Microbiology and epidemiology of cryptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/79?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of blastomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38250?source=related_link\">",
"      Oral toxicity associated with chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/10/8361?source=related_link\">",
"      Pathophysiology and treatment of fever in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/31/36338?source=related_link\">",
"      Patient information: When to worry about a fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_38_13931="ERCP for pancreatic disorders in children";
var content_f13_38_13931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential indications for ERCP for pancreatic disease in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Nonresolving acute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Idiopathic recurrent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Chronic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistently elevated pancreatic enzymes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluation of abnormalities on ultrasound, CT or MRCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic pseudocysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic duct leaks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic duct obstruction (eg, stone or stricture)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ERCP: endoscopic retrograde cholangiopancreatography; CT: computerized tomography; MRCP: magnetic resonance cholangiopancreatography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13931=[""].join("\n");
var outline_f13_38_13931=null;
var title_f13_38_13932="Use of plasma components";
var content_f13_38_13932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F69637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F69637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Composition and use of standard plasma components in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Component",
"       </td>",
"       <td class=\"subtitle1\">",
"        Composition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indications and dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        FFP, thawed plasma, and 24 hour frozen plasma (FP 24) (one unit)",
"       </td>",
"       <td rowspan=\"3\">",
"        All soluble plasma proteins from one unit of whole blood",
"       </td>",
"       <td>",
"        Correction of bleeding due to excess warfarin, vitamin K deficiency, or deficiency of multiple coagulation factors (eg, DIC, liver disease, dilutional coagulopathy) Initial dose: 15 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massive transfusion protocols",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For infusion or plasma exchange in TTP-HUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Cryo-precipitate (cryo, one unit)",
"       </td>",
"       <td rowspan=\"4\">",
"        One unit of cryo&nbsp;(volume: 10-20 mL) contains&nbsp;the cold insoluble protein from one unit of FFP; Pasteurized; contains vWF, factors VIII, XIII, fibrinogen, fibrinonectin. Some blood suppliers now provide pre-pooled cryo (one bag) comprised of 5 (or more)&nbsp;units of cryo in a volume rangling from 120 to 160 mL each/ Typically, two bags of pre-pooled cryo (ie, cryo from 10 units of FFP) are issued for therapeutic replacement of fibrinogen.&nbsp;",
"       </td>",
"       <td>",
"        Source of fibrinogen (200 mg/unit)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For bleeding in vWD: 1 unit/10 kg q 6-12 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor XIII deficiency: 1 unit/10 kg usually once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor VIII deficiency: 100 Int. units/unit. This use is outmoded; recombinant factor VIII should be used",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryo-poor plasma (one unit)",
"       </td>",
"       <td>",
"        240 mL of FFP that is depleted of cold insoluble proteins",
"       </td>",
"       <td>",
"        <p>",
"         Suitable for bleeding due to coumadin overdose, vitamin K deficiency.",
"        </p>",
"        <p>",
"         For infusion or plasma exchange in TTP-HUS",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FFP: fresh frozen plasma; S/D FFP: solvent-detergent-treated FFP; DIC: disseminated intravascular coagulation; vWD: von Willebrand disease; TTP-HUS: thrombotic thrombocytopenic purpura-hemolytic uremic syndrome; vWF: von Willebrand factor.",
"     <br>",
"      * See text and appropriate topic reviews for details concerning each of the indications listed below.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13932=[""].join("\n");
var outline_f13_38_13932=null;
var title_f13_38_13933="Specific treatment for bacterial arthritis in children";
var content_f13_38_13933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested antimicrobial regimens for the most commonly isolated pathogens causing bacterial arthritis in infants and children when results of culture and susceptibility testing are known",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathogen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parenteral agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oral agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        <em>",
"         Staphylococcus aureus",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methicillin-susceptible",
"       </td>",
"       <td>",
"        <p>",
"         Cefazolin",
"        </p>",
"        <p>",
"         Nafcillin",
"        </p>",
"        <p>",
"         Oxacillin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cephalexin",
"        </p>",
"        <p>",
"         Cloxacillin",
"        </p>",
"        <p>",
"         Dicloxacillin",
"        </p>",
"        <p>",
"         Clindamycin*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Methicillin-resistant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Clindamycin-susceptible",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Vancomycin",
"        </p>",
"        <p>",
"         Clindamycin",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Clindamycin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Clindamycin-resistant",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Vancomycin",
"        </p>",
"        <p>",
"         Linezolid",
"        </p>",
"        <p>",
"         Daptomycin",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Linezolid",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         <em>",
"          Streptococcus agalactiae",
"         </em>",
"         (Group B streptococcus)",
"        </strong>",
"       </td>",
"       <td>",
"        Penicillin",
"       </td>",
"       <td>",
"        Oral therapy not suggested in infants",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         <em>",
"          Streptococcus pyogenes",
"         </em>",
"         (Group A streptococcus)",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin",
"        </p>",
"        <p>",
"         Ampicillin",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin",
"        </p>",
"        <p>",
"         Amoxicillin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        (Pneumococcus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin-susceptible",
"       </td>",
"       <td>",
"        Penicillin",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin",
"        </p>",
"        <p>",
"         Amoxicillin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Penicillin-nonsusceptible",
"       </td>",
"       <td>",
"        <p>",
"         Cefotaxime",
"        </p>",
"        <p>",
"         Ceftriaxone",
"        </p>",
"        <p>",
"         Clindamycin*",
"        </p>",
"        <p>",
"         Linezolid",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Clindamycin*",
"        </p>",
"        <p>",
"         Linezolid",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         <em>",
"          Kingella kingae",
"         </em>",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin",
"        </p>",
"        <p>",
"         Cefotaxime",
"        </p>",
"        <p>",
"         Ceftriaxone",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Penicillin",
"        </p>",
"        <p>",
"         Cephalexin",
"        </p>",
"        <p>",
"         Cefixime",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         <em>",
"          Haemophilus influenzae",
"         </em>",
"         type b",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Cefotaxime",
"        </p>",
"        <p>",
"         Ceftriaxone",
"        </p>",
"        <p>",
"         Cefuroxime",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Amoxicillin (if susceptible)",
"        </p>",
"        <p>",
"         Cefixime",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If isolate is clindamycin-susceptible.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Clindamycin should not be used even if D-test is negative.",
"      <br>",
"       &Delta; Daptomycin should not be used in children with concomitant pulmonary involvement. It is not approved for the treatment of septic arthritis in children; the appropriate dose has not been established.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13933=[""].join("\n");
var outline_f13_38_13933=null;
var title_f13_38_13934="TNM staging esoph SCC";
var content_f13_38_13934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging of esophageal squamous cell cancer (SCC)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Primary tumor (T)*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"5\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"5\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"5\">",
"       High-grade dysplasia&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"5\">",
"       Tumor invades lamina propria, muscularis mucosae, or submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Tumor invades lamina propria or muscularis mucosae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Tumor invades submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"5\">",
"       Tumor invades muscularis propria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"5\">",
"       Tumor invades adventitia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T4",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"5\">",
"       Tumor invades adjacent structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Resectable tumor invading pleura, pericardium, or diaphragm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"5\">",
"       Unresectable tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Regional lymph nodes (N)&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"5\">",
"       Regional lymph node(s) cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"5\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"5\">",
"       Metastasis in 1-2 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"5\">",
"       Metastasis in 3-6 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"5\">",
"       Metastasis in seven or more regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"5\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"5\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Histologic grade (G)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       GX",
"      </td>",
"      <td colspan=\"5\">",
"       Grade cannot be assessed - stage grouping as G1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G1",
"      </td>",
"      <td colspan=\"5\">",
"       Well differentiated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G2",
"      </td>",
"      <td colspan=\"5\">",
"       Moderately differentiated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G3",
"      </td>",
"      <td colspan=\"5\">",
"       Poorly differentiated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G4",
"      </td>",
"      <td colspan=\"5\">",
"       Undifferentiated - stage grouping as G3 squamous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"6\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\" colspan=\"6\">",
"       Squamous cell carcinoma&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle4\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle4\">",
"       T",
"      </td>",
"      <td class=\"subtitle4\">",
"       N",
"      </td>",
"      <td class=\"subtitle4\">",
"       M",
"      </td>",
"      <td class=\"subtitle4\">",
"       Grade",
"      </td>",
"      <td class=\"subtitle4\">",
"       Tumor location &sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0",
"      </td>",
"      <td>",
"       Tis (HGD)",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       1, X",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       1, X",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IB",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       2-3",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2-3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       1, X",
"      </td>",
"      <td>",
"       Lower, X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IIA",
"      </td>",
"      <td>",
"       T2-3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       1, X",
"      </td>",
"      <td>",
"       Upper, middle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2-3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       2-3",
"      </td>",
"      <td>",
"       Lower, X",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       IIB",
"      </td>",
"      <td>",
"       T2-3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       2-3",
"      </td>",
"      <td>",
"       Upper, middle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1-2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIA",
"      </td>",
"      <td>",
"       T1-2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIIB",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       IIIC",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1-2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * At least maximal dimension of the tumor must be recorded and multiple tumors require the T(m) suffix.",
"     <br>",
"      &bull; High-grade dysplasia (HGD) includes all noninvasive neoplastic epithelia that was formerly called carcinoma in situ, a diagnosis that is no longer used for columnar mucosae anywhere in the gastrointestinal tract.",
"      <br>",
"       &Delta; Number must be recorded for total number of regional nodes sampled and total number of reported nodes with metastasis.",
"       <br>",
"        &loz; Or mixed histology including a squamous component or NOS.",
"        <br>",
"         &sect; Location of the primary cancer site is defined by the position of the upper (proximal) edge of the tumor in the esophagus.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13934=[""].join("\n");
var outline_f13_38_13934=null;
var title_f13_38_13935="Gram stain sputum 5";
var content_f13_38_13935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain sputum 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_38_13935=[""].join("\n");
var outline_f13_38_13935=null;
